

Provincial Plasma Audit Report

September 2009

This report has been submitted on behalf of the Provincial Plasma Steering Committee:

Dr. Alan Tinmouth, The Ottawa Hospital - Chair Dr. Jeannie Callum, Sunnybrook Health Sciences, Sponsor ORBCoN Central Mr. Troy Thompson, ORBCoN Central Dr. Peter Pinkerton, Consultant ORBCoN Central Dr. Yulia Lin, Sunnybrook Health Sciences Dr. Cyrus Chen Hsia, London Health Sciences Ms. Kathleen Eckert, London Health Sciences Dr. Donnie Arnold, Hamilton Health Sciences Dr. Kathryn Webert, Hamilton Health Sciences Dr. Jan Bormanis, The Ottawa Hospital Ms. Doris Neurath, The Ottawa Hospital Dr. Lois Shepherd, Kingston General Hospital Dr. Christine Cserti-Gazdewich, University Health Network Mr. Marvin Jones, Sudbury General Hospital Ms. Kathy Callaghan, Halton Health Services Ms. Joanne Guzda, Niagara Health Services Ms. Laura Harrison, The Credit Valley Hospital Mr. Robert Romans, Canadian Blood Services Ms. Nancy Heddle, McMaster Transfusion Research Program, Sponsor ORBCoN Southwest Ms. Kate Gagliardi, ORBCoN Southwest Ms. Wendy Owens, ORBCoN Northern and Eastern Ms. Debbie Lauzon, ORBCoN Central Ms. Stephanie Cope, ORBCoN Central

TABLE OF CONTENTS

1.0 Executive Summary	6
2.0 Background and Purpose	8
3.0 Design and Methodology	10
4.0 Validation Procedures	10
5.0 Determination of Appropriate/Inappropriate ratings for frozen plasma transfusions	11
6.0 Provincial Plasma Audit Results	12
Participating hospitals	12
Frozen plasma utilization	12
7.0 Appropriateness of frozen plasma transfusions	17
Indications for transfusion of frozen plasma	17
Appropriateness of orders for transfusion of frozen plasma by hospital class	19
Appropriateness of orders for transfusion of frozen plasma by region	20
Effect of presence of "guidelines" on appropriateness of transfusion of frozen plasma	20
Dose of frozen plasma transfusions	21
8.0 Conclusions and recommendations	22
Adequacy of present guidelines	22
Previous audits using present guidelines	23
Adequacy of dosage of frozen plasma	23
Adverse events associated with transfusion of frozen plasma	23
Limitations of the data	24
Lessons from this audit	24
Proposed future steps	26
9.0 Acknowledgements	27

LIST OF FIGURES

Figure 1: Provincial Plasma Disposition Data	8
Figure 2: Classifications for Transfusion of Frozen Plasma	17
Figure 3: Plasma orders with and without "guidelines"	21
Figure 4: Distribution of Doses	21

LIST OF TABLES

Table 1. Criteria Developed for Classification of orders for frozen plasma transfusion11
Table 2. Plasma products ordered, transfused or otherwise disposed of during the audit period
Table 3. Distribution of ordering, transfusion, and discarding of units of frozen plasma byhospital classification.13
Table 4. Clinical services from which orders for frozen plasma originated
Table 5. Hospital location to which frozen plasma was issued for transfusion. 15
Table 6. Clinical indications for orders of frozen plasma 16
Table 7. Summary of frequency of reasons transfusion orders for frozen plasma were deemed"appropriate", "inappropriate" or "indeterminate"
Table 8. Orders for frozen plasma for transfusion by class of hospital
Table 9. Orders for frozen plasma for transfusion by region. 20
Table 10. Significance of differences in proportion of orders deemed "appropriate","inappropriate" or "indeterminate" in hospitals with and without "guidelines" for transfusionof frozen plasma.20

List of Appendices

Appendix A: Summary of Published Guidelines for the Use of Fresh Frozen Plasma	28
Appendix B: Previous Audits of Prescribing or Use of Fresh Frozen Plasma	29
Appendix C: Hospital Specific Data	30

1.0 Executive Summary

Background and Purpose:

- Audits of frozen plasma use world-wide, including Ontario, indicate considerable inappropriate transfusion of frozen plasma when measured against published guidelines, which themselves lack an established objective basis.
- Transfusion of frozen plasma has a constellation of adverse consequences, especially transfusion-related acute lung injury (TRALI) and transfusion associated circulatory overload (TACO).
- The costs of frozen plasma transfusions are substantial and savings could accrue from the elimination of inappropriate use:
 - Reduction in the costs of collecting, processing, distribution and administration at the clinical level in hospital, of frozen plasma.
 - Diversion of frozen plasma no longer transfused to the manufacturing of plasma derivatives (IVIG and albumin) thereby reducing dependence on more expensive purchased plasma.
 - Reduction in the costs of managing complications of frozen plasma transfusion in hospital, in particular those cases requiring intensive care.

Methods:

Seventy-six (49%) of eligible hospitals, representing 88% of frozen plasma consumption in Ontario, participated. Each participating hospital collected data on frozen plasma transfusions for 5 (not necessarily consecutive) days and submitted data using a web-based data tooled designed for the purpose. Data on 573 orders for 2012 units of frozen plasma were received. Data on the indications for each transfusion encounter, including dose, were collected and the appropriateness of the clinical indication for each encounter was assessed according to criteria agreed in advance by a panel of 6 transfusion medicine physicians. Each encounter was classified into one of 3 categories – "appropriate", "inappropriate" or "indeterminate" (where the data supplied was insufficient to allow assignment to one of the other 2 categories).

Principal Findings:

- Orders for frozen plasma were deemed "appropriate" in 54.8% of cases, "inappropriate" in 28.6% and "indeterminate" in 16.6%.
- The majority of the sources of orders within the hospitals were identified as operating rooms, intensive care units, medical wards and emergency departments, providing guidance as to where best to focus measures for change.
- The most common indications cited were in support of surgical procedures and for reversal of anticoagulant effect.
- Hospitals indicating they had "guidelines" for frozen plasma transfusion had a significantly higher rate of transfusions deemed "appropriate".
- Teaching hospitals had a lower rate of frozen plasma transfusions deemed "inappropriate", but still had an "inappropriate" rate of almost 20%.

- The median dose of frozen plasma prescribed/administered was 2 units (equals 500mL) which is, for an adult, deemed less than the potentially effective amount.
- Only 29% of transfusions of frozen plasma met the criteria for both an "appropriate" indication and a sufficient dose.
- 54 or 2.7% of all units ordered were wasted for one or more of several reasons

Recommendations:


- Development and distribution of clinical practice recommendations including strategies for their implementation.
- A clear statement regarding conditions for which frozen plasma transfusion is **not** indicated should be issued.
- Clear guidance should be provided concerning the appropriate dose of frozen plasma to be prescribed to produce a significant improvement in hemostatic function, together with information on the associated risks of frozen plasma transfusion, especially TACO.
- Dissemination of advice on the use of Vitamin K **alone** for reversal of the effects of vitamin K antagonists ("warfarin effect").
- Dissemination of information on the indications and procedures for use of prothrombin complex concentrates instead of frozen plasma for **urgent** reversal of the effects of vitamin K antagonists.
- Enhancement of general awareness of potential adverse consequences of transfusion of frozen plasma
- Longer term goals include assessment of the effectiveness of the introduction of the measures recommended above and promotion of random controlled clinical trials designed to obtain evidence to define the optimal clinical use of frozen plasma.

Provincial Plasma Audit Report

"Worldwide, the largest avoidable risk to patients from transfusion is probably due to the transfusion of fresh frozen plasma (FFP) for totally inappropriate or unproven clinical indications."¹

2.0 Background and Purpose

An audit of frozen plasma transfusion was undertaken to ascertain the current ordering and utilization practices among Ontario hospitals. Despite the publication of many recommended guidelines for the use of frozen plasma, a significant proportion of frozen plasma transfusions do not meet the criteria set forth in these guidelines (See Appendix A for details and references). In addition, the use of frozen plasma generally has been growing steadily in many jurisdictions. It is noted that in Ontario, however, there has been a recent trend to decreased utilization of frozen plasma.



Provincial Plasma Disposition Data

Figure 1 Ontario Provincial Plasma Disposition data for FY 2007-2008 with the Purple bars representing the number of units transfused; the Blue bars representing the number of units Discarded; and the Yellow solid line representing the percentage of discarded plasma. Units discarded represent the frozen plasma units that are thawed and not transfused.

Frozen plasma has been available since the 1950s. The primary indication for frozen plasma transfusion is the replacement of deficiencies of clotting factors. Generally, frozen plasma is transfused with the intent to correct the deficiencies of clotting factors in patients who are bleeding or prior to surgery or invasive procedures which may be associated with bleeding complications. Frozen plasma is available as fresh frozen plasma frozen within 8 hours of collection (FFP), and frozen plasma frozen within 24 hours of collection (FP 24). Two collection procedures are used;

recovery from single unit donations and by apheresis in 250 mL or 500 mL quantities. Frozen plasma contains essentially the same concentrations of clotting factors as fresh frozen plasma with the exception of factor VIII which may be reduced by up to 25%.^{2,3} Since frozen plasma is no longer used for factor VIII replacement, these different variants are for practical purposes interchangeable and the term "frozen plasma" will be used here to include all of these variants of the product.

Over the last 40 years, safer and more effective alternatives to frozen plasma have become available for the treatment of inherited single clotting factor deficiencies such as hemophilia A or B, and for the multiple factor deficiencies associated with the use of vitamin K antagonists (e.g. warfarin) and vitamin K deficiency. Until recently, prothrombin concentrates available for use in Canada contained only three of the four vitamin K dependent factors, making the use of plasma still necessary.⁴ Around the same time that this plasma audit was being performed, a commercial concentrate containing the four vitamin K dependent factors became licensed for use in Canada eliminating the need to use plasma for emergency reversal of vitamin K antagonists.^{5,6}

Guidelines for prescribing frozen plasma have been compiled by several organizations over the last 20 years. These are summarized in appendix A and are broadly similar. They rest largely on evidence from observational studies and "expert opinion". However, recent detailed scrutiny of the existing evidence indicates that the prophylactic use of frozen plasma is not significantly or consistently effective in many of the clinical settings in which it is used.⁷ Further, while use of frozen plasma to correct clotting factor deficiency in bleeding patients would seem more justifiable, its effectiveness in this situation has not been demonstrated in any controlled clinical trial.

At least 10 audits have been performed in various jurisdictions using one or other of the sets of guidelines listed in appendix A; orders for or transfusion of frozen plasma have been deemed "inappropriate" in between 26 and 73% of cases (See Appendix B). Two audits in Ontario^{8,9} each concluded that about half of frozen plasma transfusions were "inappropriate". It should be noted that these 10 audits used a variety of criteria for assessment including the guidelines described above, which are inadequately supported by objective evidence.

Recently comparisons have been drawn between transfusion rates for red cells and plasma on the assumption that red cell transfusion practices are more uniform, being based on clearer evidence-based indications. Using this approach, the ratio of plasma to red cell consumption in 8 countries varied between 14 and 31 plasma units per 100 RBCs¹⁰ with Canada at 27 plasma units per 100 RBCs.¹¹ [Note: a higher figure implies greater plasma use]. In Canada there is inter-Provincial variation in the range of 20 to 32/100 RBCs.¹² The range in medium-sized and large hospitals in Ontario is 3 to 50/100 RBCs.¹³ These data do not distinguish between those hospitals that have services which may have increased plasma demand such as plasma exchange and the hospitals that do not. However, such programs are few and are unlikely materially to affect the overall conclusions. Thus it is difficult to see how truly consistent application of guidelines for prescribing frozen plasma could be consistent with such variability.

Through this audit of frozen plasma utilization, we are seeking to evaluate the appropriateness and variation in utilization as well as adequacy of dosage. Based on the information reviewed here, we anticipate that there will be significant inappropriate use and significant variation in use, which would offer opportunities for both cost savings and avoidance of complications associated with inappropriate transfusions.

3.0 Design and Methodology

A prospective audit was undertaken of the clinical indications and laboratory data for all transfusion episodes of frozen plasma occurring in participating Ontario hospitals for any five days, not necessarily consecutive days, between September 22 and October 19, 2008. The days chosen for audit were left to the discretion of the hospital in order to maximize the numbers and enable each site to balance workload and staffing. The data were collected using a web-based audit tool developed for this audit (created in collaboration with Nextmove Inc.). Each site was pre-coded by their MAK code, which is assigned by Canadian Blood Services for any site receiving blood and blood components. Access was restricted to the hospital by user ID and password. Data variables for collection were chosen by a subgroup of the Plasma Steering Committee.

A pilot study involving four hospitals was conducted over a five day period from May 26 - 30, 2008. The pilot was used to test the functionality of the tool and to obtain feedback from the pilot hospitals regarding its use. Based on feedback from the participating hospitals, revisions were made to the audit tool prior to the formal conduct of the audit.

Elements required for identification of patients (first name, last name, hospital identification number) were entered on log sheets located only at the participating hospital. Patients were assigned an anonymous study code number which was used to enter and identify patients in the secure database.

The data elements collected included:

- Hospital site
- Patient care area
- Date of transfusion
- Patient identification by study code number
- Patient age (year of birth) and Gender
- Indication for plasma transfusion
- Number of units ordered
- Ordering physician specialty
- Final disposition of product (if not transfused)

4.0 Validation Procedures

Verification and validation procedures took place during the data collection period and at the end of the final data entry period (October 2008). As part of the verification process, all the data were reviewed for any duplicate entries or any discrepant entries. 15 hospitals were contacted regarding thirty-six (36) problematic entries. 35/36 problematic entries were due to number of plasma units ordered not matching the number of plasma units transfused. In 29 cases the units transfused were the 500 mL apheresis units which are equivalent to two units. The remainder of cases was due to missing data. Staff reviewed 10% of the manual entry sheets from a random sample of participating hospitals and compared them to the web-based data for consistency to confirm a match between the two entries. There was a 98% (59/60) agreement rate between the manual entry sheets and the web-based data with all discrepancies found in the random sample being rectified.

It is concluded that discrepancies in the database in general were sufficiently rare that they

would not materially affect the analysis and /or conclusions.

Reporting Results to Participating Hospitals

The details for each hospital's individual patient/transfusion data together with the interpretation as "Appropriate", "Inappropriate" or "Indeterminate" for each case are contained in Appendix C. The hospital identities are coded for confidentiality reasons. When this report is issued and copies sent to hospitals, individual participating institutions will be informed of their code so that they may review the interpretation of the data they submitted but will not be able to identify the source of any other institution's data.

5.0 Determination of Appropriate/Inappropriate ratings for frozen plasma transfusions

The criteria for assessing the appropriateness of each plasma order were developed by 6 volunteer Hematologists (see table 1). These criteria were based on published plasma guidelines, but the specific criteria for appropriateness were very liberal to avoid overestimating the number of inappropriate transfusions especially given the limited clinical and laboratory data that was collected as part of the audit. The indeterminate rating was used when there was insufficient evidence from the literature to judge appropriateness or insufficient clinical data were provided. Appropriate, inappropriate and indeterminate transfusions were subclassified by clinical indication.

Each order was reviewed and independently rated by two Hematologists. For any discrepancies in either the rating of appropriate, inappropriate or indeterminate, or the sub classification, the final rating was reached by consensus between the two hematologists.

Code	Appropriate
A1	 Reversal of coumadin/warfarin or vitamin K deficiency Bleeding Pre- or post-transfusion INR >1.5 and/or PTT >1x upper limit of normal.
A2	 Coagulopathy other than coumadin or vitamin K deficiency Urgent intervention or surgery Pre- or post- transfusion INR >1.5 and/or PTT>1x upper limit of normal.
A3	 Coagulopathy other than coumadin or vitamin K deficiency Bleeding Pre- or post- transfusion INR >1.5 and/or PTT >1x upper limit of normal
A4	 "Massive transfusion" Pre- or post- transfusion INR>1.5 and/or PTT >1x upper limit of normal
A5	 Apheresis/plasma exchange or TTP Regardless of coagulation status
A6	 Peri-surgical bleeding Pre- or post- transfusion INR>1.5 and/or PTT>1x upper limit of normal.

Table 1 Criteria developed for classification of orders for frozen plasma transfusion as "appropriate",

 "inappropriate" or "indeterminate".

	Inappropriate
I1	 Reversal of coagulation defect due to coumadin/warfarin or vitamin K deficiency Absence of bleeding
I2	 INR ≤ 1.0 pre- transfusion/normal PTT (and normal post-procedure if available) Irrespective of bleeding status or procedure status
I3	 INR 1.1 – 1.5 pre- transfusion/ normal PTT (and normal post-procedure if available) Irrespective of bleeding status or procedure status
I4	Heparin reversal (regardless of INR)
15	Volume replacement
16	 Reversal of coagulation defect other than coumadin/warfarin or vitamin K or heparin Pre- or post- transfusion INR>1.5 and/or PTT>1x upper limit of normal. No bleeding or surgery/procedure
	Indeterminate
M1	No laboratory coagulation data pre- or post- transfusion
M2	No laboratory coagulation data pre- transfusion (with normal coagulation results post- procedure)
M3	 Abnormal coagulation – diagnosis unknown, Not bleeding Procedure unknown
M4	 "Massive transfusion" Pre- or post- transfusion INR<1.5 and/or PTT <1x upper limit of normal or no laboratory coagulation data available
M5	 Abnormal coagulation pre- or post- transfusion Bleeding unknown

6.0 Provincial Plasma Audit Results

Participating hospitals

Seventy-six of 155 eligible hospitals (49%) participated in the Provincial audit. (Minimal plasma usage and increased workload involved in taking part were common reasons for non-participation). The participating hospitals represent 88% of the frozen plasma transfused in the Province.¹³ The hospital sites were classified into three different types of institutions: 16 small hospitals (< 100 beds), 44 community hospitals (> 100 beds) and 16 teaching hospitals (sites affiliated with an academic centre). The data collected primarily reflect plasma used by the adult population.

Frozen plasma utilization

Among the participating hospitals 65 sites had requests for frozen plasma and 11 sites had no requests for frozen plasma during the audit period. There were a total of 573 requests for 2012 units (250 ml equivalents). The total number of units transfused was 1909. The breakdown for the types of units transfused or otherwise disposed of is provided in Table 2 which incorporates aggregate data for all participating hospitals.

573
2012
1909*
1308
55
211
124
48
6
49

 Table 2 Units of various plasma products ordered, transfused or otherwise disposed of during the audit
 period.

* 250 mL equivalents

The distribution of orders for frozen plasma by hospital classification, together with information on units transfused, ordered and not transfused, broken in processing or discarded is provided in Table 3.

 Table 3 Distribution of ordering, transfusion, and discarding of units of frozen plasma by hospital
 classification.

	All	Small Hospitals (n=10)	Community Hospitals (n=39)	Teaching Hospitals (n=16)
Total # of orders	573	22 (3.8%)	278 (48.5%)	273 (47.6%)
Median # orders per hospital (min-max)	573	1 (1-6)	6 (1-28)	11 (1-44)
# of units ordered	2012	61 (3.0%)	854 (42.4%)	1097 (54.5%)
Median # units ordered per hospital (min-max)	2012	2 (1-6)	2 (1-16)	4 (1-18)
# of units transfused	1909	60 (3.1%)	821 (43.0%)	1028 (53.9%)
Median # units transfused per hospital (min-max)	1909	2 (1-6)	2 (1-16)	4 (1-18)
# of units discarded	48	0	19	29
# of units broke	6	0	5	1
# of units ordered/ not thawed	49	1	9	39

Table 4 presents the data defining the clinical services from which orders for frozen plasma originated. General surgery, internal medicine and emergency physicians each represented greater than 10% of the total number of orders for frozen plasma. Critical care and cardiovascular surgery were the second and third largest users of frozen plasma in teaching hospitals but overall they represent 8.4% and 7.3% all frozen plasma orders, respectively.

Specialty	Total # of orders (%)	Small Hospitals # of orders (%)	Community Hospitals # of orders (%)	Teaching Hospitals # of orders (%)
Surgery: General	94 (16.4)	3 (13.6)	48 (17.3)	43 (15.8)
Internal Medicine	87 (15.2)	3 (13.6)	63 (22.7)	21 (7.7)
Emergency	72 (12.6)	4 (18.2)	48 (17.3)	20 (7.3)
Critical care: medicine	48 (8.4)		19 (6.8)	29 (10.6)
Surgery: Cardiovascular	42 (7.3)		4 (1.4)	38 (13.9)
Anaesthesia	33 (5.8)		15 (5.4)	18 (6.6)
General Practice/Family Medicine	31 (5.4)	11 (50.0)	19 (6.8)	1 (0.4)
Surgery: Orthopedic	24 (4.2)		16 (5.8)	8 (2.9)
Other	23 (4.0)		5 (1.8)	18 (6.6)
Hematology	21 (3.7)		3 (1.1)	18 (6.6)
Gastroenterology	20 (3.5)		10 (3.6)	10 (3.7)
Cardiology	15 (2.6)		4 (1.4)	11 (4.0)
Critical care: cardiac	15 (2.6)		5 (1.8)	10 (3.7)
Nephrology	12 (2.1)		7 (2.5)	5 (1.8)
Obstetrics & Gynecology	11 (1.9)	1 (4.6)	5 (1.8)	5 (1.8)
Surgery: Neurosurgery	9 (1.6)		2 (0.7)	7 (2.6)
Oncology	7 (1.2)		1 (0.4)	6 (2.2)
Respirology	4 (0.7)		2 (0.7)	2 (0.7)
Neonatology	2 (0.3)			2 (0.7)
Dermatology	1 (0.2)			1 (0.4)
Neurology	1 (0.2)		1 (0.4)	
Pediatrics	1 (0.2)		1 (0.4)	
Other				
Transplant program	9 (1.6)			9 (3.3)
Surgery: Vascular	4 (0.7)		1 (0.4)	3 (1.1)
Hospitalist	3 (0.5)		3 (1.1)	
Liver Transplant	2 (0.3)			2 (0.7)
Surgery: Urology	2 (0.3)			1 (0.4)
Nurse Practitioner	1 (0.2)		1 (0.4)	
Unknown	2 (0.3)			2 (0.7)
Urology				1 (0.4)
Total	573	22	278	273

 Table 4 Clinical services from which orders for frozen plasma originated.

Table 5 shows the location within the hospitals to which frozen plasma was issued and where transfusion of frozen plasma was assumed to have taken place. The operating room and the intensive care unit transfused 23.2% and 21.5% respectively of all the frozen plasma units transfused. The next most frequent areas for transfusion were general medical wards and the emergency department.

Hospital location	Total # of orders (%)	Small Hospitals # of orders (%)	Community Hospitals # of orders (%)	Teaching Hospitals # of orders (%)
Operating Room (OR)	133 (23.2)	2 (9.1)	37 (13.3)	94 (34.4)
Intensive-Critical care (ICU)	123 (21.5)	1 (4.6)	67 (24.1)	55 (20.2)
Medical Ward	94 (16.4)	10 (45.4)	51 (18.4)	33 (12.1)
Emergency	84 (14.7)	7 (31.8)	54 (19.4)	23 (8.4)
Surgical Ward	38 (6.6)	1 (4.6)	36 (13.0)	1 (0.4)
Cardiovascular ICU	26 (4.5)		7 (2.5)	19 (7.0)
Apheresis	19 (3.3)			19 (7.0)
Recovery Room	18 (3.1)		3 (1.1)	15 (5.5)
Other	17 (3.0)	1 (4.6)	9 (3.2)	7 (2.6)
Coronary Care Unit	11 (1.9)		9 (3.2)	2 (0.7)
Dialysis	3 (0.5)		3 (1.1)	
Outpatient Clinic	3 (0.5)		1 (0.4)	2 (0.7)
Neonatal ICU	2 (0.3)			2 (0.7)
Diagnostic Imaging	1 (0.2)			1 (0.4)
Unknown	1 (0.2)		1 (0.4)	
Other				
Patient Room	4 (0.7)			4 (1.5)
Birthing Suite			1 (0.4)	
Obstetrics	2 (0.3)	1 (4.6)		
Telemetry	2 (0.3)		2 (0.7)	
Burn Ward	1 (0.2)			1 (0.4)
Transplant Unit	1 (0.2)			1 (0.4)
Rehabilitation	1 (0.2)		1 (0.4)	
Neurology ICU	1 (0.2)			1 (0.4)
Home Transfusion	1 (0.2)		1 (0.4)	
Medicine-Cardio	1 (0.2)		1 (0.4)	
Plasma not issued	3 (0.5)		3 (1.1)	
Total	573	22	278	273

 Table 5 Hospital location to which frozen plasma was issued for transfusion.

Table 6 shows the broad indications for which frozen plasma was ordered. The most common indications leading to orders for frozen plasma were in connection with surgery (31.4%) and for anticoagulant reversal (20.2%).


Procedure/ Clinical Indication	Total # of orders (%)	Small Hospitals # of orders (%)	Community Hospitals # of orders (%)	Teaching Hospitals # of orders (%)
Surgery	180 (31.4)	4 (18.2)	68 (24.5)	109 (39.9)
Anticoagulant Reversal	116 (20.2)	3 (13.6)	98 (35.3)	15 (5.5)
Coagulopathy (Liver disease, DIC, etc)	64 (11.2)		39 (14.0)	25 (9.2)
Massive Transfusion	42 (7.3)		17 (6.1)	25 (9.2)
GI Bleed	25 (4.4)	3 (13.6)	12 (4.3)	10 (3.7)
Other Bleed	23 (4.0)	4 (18.2)	11 (4.0)	8 (2.9)
Plasma exchange (therapeutic apheresis)	22 (3.8)		3 (1.1)	19 (7.0)
Drain/Line Insertion	10 (1.7)			10 (3.7)
Sepsis	11 (1.9)		6 (2.2)	5 (1.8)
Liver Transplant	8 (1.4)			8 (2.9)
Leukemia	7 (1.2)		1 (0.4)	6 (2.2)
Unknown	13 (2.3)		6 (2.2)	6 (2.2)
Image Guided Therapy	6 (1.0)	4 (18.2)	1 (0.4)	1 (0.4)
Thoracentesis	5 (0.9)			5 (1.8)
Paracentesis	4 (0.7)		4 (1.4)	
Central Line Placement	3 (0.5)			3 (1.1)
Volume Expansion	3 (0.5)		3 (1.1)	
Other Transplant	2 (0.3)			2 (0.7)
Trauma	2 (0.3)			2 (0.7)
Liver Biopsy	2 (0.3)			2 (0.8)
Cardiac Catheterization	1 (0.2)			1 (0.4)
Fine Needle aspirate	1 (0.2)		1 (0.4)	
Pleural Effusion	2 (0.3)		1 (0.4)	1 (0.4)
Miscellaneous	21 (3.7)	4 (18.2)	7 (2.5)	10 (3.7)
Total	573	22	278	273


 Table 6
 Clinical indications for orders of frozen plasma

7.0 Appropriateness of frozen plasma transfusions

Indications for transfusion of frozen plasma

Figure 2 Of the 573 requests for Frozen Plasma, 314 (54.8%) were classified as appropriate while 164 (28.6%) were inappropriate and 95 (16.6%) were indeterminate.





314/573 (54.8%) of plasma orders classified as Appropriate 164/573 (28.6%) of plasma orders classified as Inappropriate 95/573 (16.6%) of plasma orders classified as Indeterminate

The most common indications deemed "appropriate" were in relation to surgery and for reversal of anticoagulant effect. The frequency of the various reasons for orders of frozen plasma that were deemed "inappropriate" or "indeterminate" are given in Table 7 in which the proportion of the different categories defined in Table 1 are listed in descending order.

Table 7 Summary of frequency of reasons transfusion orders for frozen plasma were deemed"appropriate", "inappropriate" or "indeterminate".

Code Defining "Appropriate"	# of orders (%)	Code Description
A3	96 (16.8)	 Coagulopathy other than coumadin or vitamin K deficiency Bleeding Pre- or post- transfusion INR >1.5 and/or PTT >1x upper limit of normal
A6	80 (14.0)	 Peri-surgical bleeding Pre- or post- transfusion INR>1.5 and/or PTT>1x upper limit of normal.
A2	43 (7.5)	 Coagulopathy other than coumadin or vitamin K deficiency Urgent intervention or surgery Pre- or post- transfusion INR >1.5 and/or PTT>1x upper limit of normal.
A1	37 (6.4)	 Reversal of coumadin/warfarin or vitamin K deficiency Bleeding Pre- or post-transfusion INR >1.5 and/or PTT >1x upper limit of normal.
A4	35 (6.1)	 "Massive transfusion" Pre- or post- transfusion INR>1.5 and/or PTT >1x upper limit of normal
A5	23 (4.0)	 Apheresis/plasma exchange or TTP Regardless of coagulation status

Code Defining "Inappropriate"	# of orders (%)	Code Description
13	90 (15.7)	 INR 1.1 – 1.5 pre- transfusion/ normal PTT (and normal post-procedure if available) Irrespective of bleeding status or procedure status
11	41 (7.2)	 Reversal of coagulation defect due to coumadin/warfarin or vitamin K deficiency Absence of bleeding
16	15 (2.6)	 Reversal of coagulation defect other than coumadin/warfarin or vitamin K or heparin Pre- or post- transfusion INR>1.5 and/or PTT>1x upper limit of normal. No bleeding or surgery/procedure
I4	10 (1.7)	Heparin reversal (regardless of INR or PTT)
12	7 (1.2)	 INR ≤ 1.0 pre- transfusion/normal PTT (and normal post-procedure if available) Irrespective of bleeding status or procedure status
15	1 (0.2)	Volume replacement

Code Defining "Indeterminate"	# of orders (%)	Code Description
M5	31 (5.4)	Abnormal coagulation pre- or post- transfusionBleeding unknown
M1	27 (4.7)	No laboratory coagulation data pre- or post- transfusion
M2	17 (3.0)	No laboratory coagulation data pre- transfusion (with normal coagulation results post-procedure)
M3	12 (2.1)	 Abnormal coagulation – diagnosis unknown, Not bleeding Procedure unknown
M4	8 (1.4)	 "Massive transfusion" Pre- or post- transfusion INR<1.5 and/or PTT <1x upper limit of normal or no laboratory coagulation data available

Appropriateness of orders for transfusion of frozen plasma by hospital class

The proportion of orders deemed "appropriate", "inappropriate" or "indeterminate" by hospital class is shown in table 8. The only significant differences to emerge on comparison of the various categories was in respect of the teaching hospitals vs. the community hospitals for appropriate orders (higher proportion, 64.5% vs. 45.7%) and inappropriate orders (lower proportion, 19.4% vs. 36.7%); in both cases p<0.0001.

Table 8 Orders for frozen plasma for transfusion by class of hospital

Orders						
Hospital size	Appropriate	Inappropriate	Indeterminate			
Small Hospital	11 (50.0%)	9 (40.9%)	2 (9.1%)	22		
Community Hospital	127 (45.7%)	102 (36.7%)	49 (17.6%)	278		
Teaching Hospital	176 (64.5%)	53 (19.4%)	44 (16.1%)	273		
Total	314	164	95	573		

Appropriateness of orders for transfusion of frozen plasma by region

The proportion of orders classified as "appropriate', "inappropriate" or "indeterminate" did not differ significantly from one region of the Province to another and this was true regardless of the class of hospital being compared (Table 9).

		Orders					
Region	Appropriate	Inappropriate	Indeterminate	264			
Central	150 (56.8%)	67 (25.4%)	47 (17.8%)				
SW	119 (53.6%)	68 (30.6%)	35 (15.8%)	222			
NE	45 (51.7%)	29 (33.3%)	13 (14.9%)	87			
Total	314	164	95	573			

 Table 9 Orders for frozen plasma for transfusion by region.

Effect of presence of "guidelines" on appropriateness of transfusion of frozen plasma


There was a significantly greater number of appropriate (65.7% vs. 46.3%) and correspondingly lower number of inappropriate transfusions (20.7% vs. 34.8%) in hospitals with "guidelines" for the appropriate use of frozen plasma as compared to those hospitals that did not have "guidelines" (see table 10 and figure 3). The audit tool posed the simple question "Does your facility have institutional guidelines for the use frozen plasma?" No attempt was made to acquire more detail concerning the nature and content of the "guidelines" in use.

There were 22 hospitals reporting the existence of "guidelines" and 43 hospitals did not have such "guidelines" for the use of frozen plasma. (11 hospitals did not report).

Table 10 Significance of differences in proportion of orders deemed "appropriate", "inappropriate" or "indeterminate" in hospitals with and without "guidelines" for transfusion of frozen plasma.

Orders	Guidelines	No Guidelines	P value	
Appropriate	165 (65.7%)	149 (46.3%)	p<0.0001	
Inappropriate	52 (20.7%)	112 (34.8%)	p<0.0003	
Indeterminate	34 (13.5%)	61 (18.9%)	0.08	

Figure 3 Differences in proportion of orders deemed "appropriate", "inappropriate" and "indeterminate" in hospitals with and without guidelines for transfusion of frozen plasma.




Plasma Orders (n=573)

Dose of frozen plasma transfusions

The most common dose of frozen plasma transfused was 2 units (42.4% of transfusions) and the next most common dose was 4 units (30.2% of transfusions) (Figure 4). For an average 70 kg patient, the 2 unit dose represents a dose of about 7 ml/kg which is below the recommended dose of 10-15 mls/kg. Assuming a 70 kg patient weight, the 10-15 ml/kg recommended dose is equivalent to 3-4 250mL units.

When data on the appropriateness of the order for frozen plasma and for adequacy of dosage are combined, only 29% of all transfusions met the criteria for both an appropriate indication and the recommended dose range.

Figure 4 Distribution of doses of plasma transfused as reported by audit participants (1 "unit" is equivalent to 250 mL of random donor plasma



8.0 Conclusions and recommendations

Discussion

Reviews of literature and of the results of the current audit reported here raise several issues for discussion which will lead to recommendations for improvement in practice.

Three main areas offer the opportunity for savings – reduced use of inappropriate frozen plasma transfusions, elimination of the expense of managing complications caused by inappropriate transfusions and increased self sufficiency for the production of Canadian source plasma protein products. This audit confirms that prescribing outside of guidelines is not uncommon. Thus, efforts are needed to ensure implementation of guidelines into practice which would reduce the use of frozen plasma and result in significant cost-savings for the Province. The "hidden" costs of complications caused by frozen plasma transfusions which should not have been given would be eliminated. Donor plasma can be re-directed for fractionation thus reducing the reliance on more expensive foreign sources. Furthermore, education of those prescribing and administering transfusions designed to prevent complications could be promoted through the outcomes of this audit.

Adequacy of present guidelines

Recent reviews of the published guidelines for use of frozen plasma (see appendix A) have emphasized their lack of foundation on high quality evidence, depending as they do largely on observational studies and "expert opinion" rather than on results of random controlled clinical trials.¹⁴ There is a general lack of evidence that transfusion of frozen plasma is effective in preventing bleeding in a variety of clinical settings. Evidence is lacking that the results of laboratory tests designed to assess coagulation function are predictors of bleeding in populations likely to be treated with frozen plasma. Recent studies have confirmed that frozen plasma transfusion is ineffectual in correcting mild elevations of the international normalized ratio or prothrombin time.^{15,16} Taken together, these observations suggest that there may be even more potential for reducing the use of frozen plasma transfusion beyond that to be achieved by following current published clinical practice guidelines.

Thus, guidelines used have significant deficiencies but at the time this audit was designed were the only generally recognized criteria available upon which to base an audit of Provincial use of frozen plasma. Since then, a new set of guidelines have been published which include a novel approach in attempting to define situations in which frozen plasma should <u>not</u> be used.¹⁷

Examples of situations in which it is recommended that frozen plasma <u>not</u> be prescribed:¹⁷

- Plasma should not be administered prophylactically to patients with normal coagulation tests submitted to high-risk surgery or invasive diagnostic procedures
- Plasma is not the first choice to neutralize anticoagulation with coumarin agents in bleeding patients and prothrombin complex concentrates should be given instead. The administration of plasma can be taken into consideration when no prothrombin complexes are available
- Plasma should not be given to correct hypovolemia in the absence of massive bleeding
- Plasma should not be used routinely for plasma exchange

Previous audits using present guidelines

This audit of frozen plasma use has involved more transfusions/patients than all but one of those listed in Appendix B. Those 10 audits of frozen plasma transfusion have been reported world-wide using the criteria of the guidelines listed in appendix A. Overall, between 26% and 73% of orders or transfusions of frozen plasma did not meet the specified criteria. Two of these studies were conducted in Ontario^{8,9} and concluded that about half of transfusions of frozen plasma were "inappropriate". Despite the publication of these two audits, no significant improvement in appropriate ordering practices has been demonstrated in Ontario during this audit.

Even with guidelines with identifiable shortcomings, there remain a large number of transfusions of frozen plasma that should almost certainly not have been carried out.

Adequacy of dosage of frozen plasma

Only 29% of all frozen plasma transfusions administered during the audit met the criteria for both an appropriate indication and the recommended dosage range. Several recent reports have emphasized that the volumes of plasma required to correct *in vitro* clotting defects are usually greater than the doses commonly prescribed¹⁸⁻²¹ and therefore raise the risk of transfusion-associated circulatory overload (TACO).

The generally accepted minimal effective dose is 10-15mL/kg of body weight ²² which translates to 750 - 1,000 mL for an average sized individual. Shulman and Bijsterveld ²¹ suggest that 2,000 mL would be required to reduce a high INR due to warfarin effect to less than 1.5.

Adverse events associated with transfusion of frozen plasma

The adverse events associated with the transfusion of frozen plasma have until recently been overshadowed by concerns regarding incompatible red cell transfusion and bacterial contamination principally associated with platelet use. Recently, frozen plasma has received more attention. Transfusion-related acute lung injury (TRALI) is mediated in many (but not all) cases by antibodies in donor plasma which react with recipient leucocytes, particularly in patients "primed" by comorbid pulmonary complications.²³ The frequency of TRALI is hard to estimate but a figure of 1:5000 transfusions has some general support.²² The fatality rate from TRALI is uncertain but a figure of 10% of cases is quoted. TRALI has proved the commonest cause of transfusion associated death in the UK SHOT hemovigilance program up to 2006;²⁴ 39 of 109 deaths were attributed to TRALI. Since the antibodies in donor plasma which mediate many cases of TRALI are commonly found in female donors who have been pregnant, female derived plasma has been eliminated as a source of frozen plasma with reduction but not complete prevention of TRALI. Thus, the UK SHOT program noted TRALI with a frequency of 1:65,000 units of frozen plasma transfused in 1999-2004 compared with 1:317,000 units in 2005-2006 after elimination of female derived plasma.²⁴

Transfusion-associated circulatory overload (TACO) has been recognized for many years and represents the resultant effect of the volume and rate of transfusion, and the cardio-pulmonary status of the recipient. It is common but has only recently become reportable to hemovigilance schemes in North America and the UK. Estimates of frequency of TACO vary from 1:700 red cell transfusions in general²⁵ to 1:100 in elderly recipients.²⁶ Forty-nine of 321 transfusion associated deaths reported to the French Hemovigilance System from 1995-2002 were attributed to TACO.²⁷ Six of 7 transfusion fatalities reported to the Quebec Hemovigilance System in 2007 were attributed

to TACO.²⁸

Major allergic reactions and bacterial contamination remain rare but serious complications of frozen plasma transfusion. Occasional cases of ABO incompatible transfusion reactions occur usually due to transfusion of high titre anti-A or anti-B plasma from group O donors. Minor adverse events, the precise frequency of which is unknown, include febrile reactions, minor allergic phenomena and transient hypotension.

Thus, transfusion of frozen plasma carries significant risks of severe, even fatal, adverse effects, the full significance of which is only now coming fully to light.

It should be noted that this audit was not designed to capture data on rates of transfusion reactions; this would require a larger study with provision for clinical follow-up and review.

Limitations of the Data

After evaluation of the audit data it was determined that there were some limitations to the data that needed to be disclosed.

Participating hospitals were unable to choose two clinical indications. (e.g. a site could not choose both anticoagulant reversal and preoperative);

The definition for minor bleeding and bleeding was stated in the audit questions however this information is often difficult to obtain without doing a full chart review;

During the audit period, a prothrombin complex concentrate containing factors II, VII, IX and X (OctaplexTM) was introduced and its use was not considered in the development of the rating criteria;

The pilot included the patient's weight which proved to be inconsistently available and was therefore removed from the final audit tool;

Point of care coagulation testing may have been utilized for orders that did not have pretransfusion coagulation results entered. This data may not have been available to the audit reporter;

The audit period chosen was for 5 days (not necessarily consecutive) which limits the amount of data collected.

Lessons from this audit

This audit has provided a valuable "snapshot" of current practice in transfusing frozen plasma in Ontario and provides a number of areas for improvement, both quantitatively and qualitatively.

- (i) Numerous transfusions (at least 29%) are given without meeting the indications defined by current guidelines. It has been suggested that reasons for not prescribing frozen plasma should be put forward and that recording of indications for specific transfusion orders would provide an element of clarity in decision-making.⁷ Inappropriate transfusions confer risk without benefit to the recipient.
- (ii) The dose of frozen plasma administered (1 or 2 units) in about half of cases was insufficient to meet the usually accepted effective dose, thus exposing the recipient to risk with minimal benefit.
- (iii) Of all transfusions of frozen plasma audited, less than 30% were given both for an indication deemed appropriate and meeting the minimal dosage criteria.
- (iv) Significant numbers of frozen plasma transfusions were given for

indications regarded as clinically inappropriate such as reversal of heparin effect or "volume replacement" for which specific or better alternatives are available.

- (v) Hospitals associated with an academic medical centre ("teaching hospitals") appear to have a lower rate of inappropriate transfusion of frozen plasma. Nevertheless, the rate of inappropriate use of frozen plasma in these institutions remains unacceptably high.
- (vi) The existence of hospital-specific protocols for ordering and issuing frozen plasma is associated with a significantly diminished proportion of inappropriate transfusions of frozen plasma. While such protocols themselves may not alone be sufficient to improve the appropriate use of blood products, they represent an essential part of an institutional culture that will improve their use.
- (vii) A considerable number of frozen plasma transfusions were given to reverse the effects of vitamin K antagonists. While it is unclear from the data collected how many of these were truly required on the basis of the clinical urgency of the situation, the recent licensing and availability of prothrombin complex concentrates in Canada (OctaplexTM) and the judicious use of vitamin K alone should largely replace frozen plasma for this purpose.
- (viii) Evidence is accumulating worldwide that frozen plasma has its own pattern of serious adverse events, particularly TRALI and TACO. While the risk of TRALI has been mitigated by changes in donor acceptability criteria (exclusion of plasma where possible from female donors), the risk has not been eliminated. TACO is beginning to be more fully recognized as a serious, potentially fatal complication of transfusion in general, including plasma. The administration of a dose adequate to produce the desired effect enhances this risk.
- (ix) Financial savings and savings in morbidity and mortality could accrue from more rational use of frozen plasma. Financial savings could accrue from removing the cost of processing, distributing, storing and issuing the full quantities of frozen plasma currently consumed. An estimate of the cost of frozen plasma units that are inappropriately transfused is \$247,000 per month, (8500 units transfused per month x \$100 unit* x 29%), approximately 3 million dollars annually. Plasma not required for transfusion as frozen plasma to patients could be diverted to production of IVIG from Canadian plasma, so reducing the cost of purchasing non-Canadian plasma for fractionation for Canadian IVIG consumption and increasing the security of the products for Canadians. The savings in suffering could accrue from the withholding of inappropriate transfusions, with concomitant financial savings from avoidance of the considerable expense of caring for these often severe and life-threatening complications.

* Cost estimate from CBS is \$99 for 1 unit of frozen plasma (fiscal year 2007/8 estimate)

Recommendations for improvement in frozen plasma transfusion practice

It is clear that there is a need and opportunity for improvement in transfusion practice in respect of frozen plasma. Vigorous educational measures suggested by the outcomes of this audit which can be undertaken promptly include:

- (i) introduction of clinical practice recommendations including strategies for implementation;
- (ii) a clear statement of conditions for which frozen plasma transfusion is *not* indicated should be issued;
- (iii) a clear statement concerning the adequacy of the dose of frozen plasma required to produce a significant improvement in hemostatic function together with the risk of adverse effects of such dosage;
- (iv) dissemination of advice on the use of vitamin K alone for reversal of the effects of vitamin K antagonists (VKA) ("warfarin effect") where time permits;
- (v) dissemination of information on indications and procedures for the use of prothrombin complex concentrates for urgent reversal of VKA effects;
- (vi) enhanced general awareness of the potential adverse consequences of transfusion of frozen plasma

Proposed future steps

- (i) The implementation of new clinical practice recommendations should be further evaluated to determine the uptake and effectiveness in improving transfusion practice in respect of frozen plasma.
- (ii) Randomized controlled trials should be carried out to determine the effectiveness of frozen plasma in various clinical settings in which it is now commonly used, with a view to establishing objective evidence as to its efficacy or otherwise;
- (iii) Well-designed multi-centre random controlled trials should be mounted to determine the optimal transfusion policy for resuscitation and massive transfusion to address the optimal relative proportion of red cells, platelets and frozen plasma.

9.0 Acknowledgements

ORBCoN would like to acknowledge the following:

The Transfusion Medicine Staff at all participating facilities The Ministry of Health and Long Term Care for providing funding to support this audit The Plasma Audit Criteria/Coding Working Group: Dr. Jeannie Callum, Dr. Peter Pinkerton, Dr. Alan Tinmouth, Dr. Cyrus Hsia, Dr. Donnie Arnold and Dr. Yulia Lin The Plasma Audit Report Writing Committee: Dr. Alan Tinmouth, Mr. Troy Thompson, Dr. Jeannie Callum, Dr. Peter Pinkerton and Dr. Donnie Arnold The Provincial Plasma Audit Steering Committee McMaster Transfusion Research Program (MTRP)

Special thanks to: Dr. Ben Saxon, former Medical Director of the Toronto Centre CBS for his foresight in suggesting the concept of holding a provincial plasma audit "day", the catalyst to making this happen.

Guideline	Single factor deficiency	Multiple factor deficiency	Reversal of warfarin effect	Liver disease	Surgical bleeding, massive transfusion	Volume replacement Not indicated	
British Committee for Standards in Haematology ^{29,} ₃₀	No safe fractionated product available	Multiple factor deficiencies with severe bleeding +/- DIC	Only in presence of severe bleeding. Partial effect only	Doubtful value. Monitor coagulation for effectiveness	If, and amount, guided by timely tests of coagulation		
College of American Pathologists ³¹ No safe fractionated or single factor product availableActive bleeding. PT 1.5x mid- point normal range, PTT 1.5x top of normal rangeNo specific recommendationNo safe bleeding. PT urgent surgeryNo specific recommendation			Active bleeding or before invasive procedure + laboratory evidence of coagulopathy	Contra- indicated			
Canadian Medical Association32Concentrates preferredActive bleeding or urgent surgery with significant increase inSevere bleeding or urgent surgery.Actua PT, IN elevat surgery.		Actual bleeding. PT, INR, PTT elevated. Not indicated for pre- procedure prophylaxis if INR=<2.0	Severe bleeding in presence if possible of laboratory evidence of coagulopathy	Not indicated			
Australian Natl. Health and Med. Res. Council ³³	Specific factors if available	Active bleeding	Life- threatening bleeding	May be appropriate with active bleeding and evidence of coagulopathy.	Bleeding with coagulopathy	Not indicated	
AmericanOnly ifSociety ofspecificAnesthesiol-concentratesogists ³⁴ are notavailable		Microvascular bleeding. PT or PTT >1.5x normal	Urgent reversal	No comment	Active bleeding when timely laboratory tests are not available	Contra- indicated	

Appendix A – Summary of Published Guidelines for the Use of Fresh Frozen Plasma

Reference	Data Year and Country	Guideline Used	% Inappropriate use and comment
Jones et al. ³⁵	UK 1996	BCSH ²⁸	37% of 41 patients, 216 units
Prabitha et al. ³⁶	Malaysia 1998	Unknown	69% of 931 transfusions, 2665 units
Luk et al. ⁸	Canada 1999	Canadian ³¹	45% of 358 patients, 2372 units
Schofield et al. ³⁷	Australia 2000	Australian ³²	63% of 669 patients
Chng et al. ³⁸	Singapore 2001	College of American Pathologists ³⁰	73% of 359 transfusions, 932 units
Kakkar et al. ³⁹	India 2002-3	BCSH ²⁸	60% of 504 transfusions, 1761 units
Hui et al. ⁴⁰	Australia 2002-3	Australian ³²	26% inappropriate/indeterminate, 70/268 transfusions
Atkinson ⁴¹	UK 2004-5	BCSH ²⁸	32% of 137 transfusions, 114 patients
Yeh et al. ⁴²	Taiwan 2003-4	BCSH ²⁸	70% of 8,248 orders, 38,772 units
Lauzier et al. ⁹	Canada 2001-2	Canadian ³¹	47.6% 225 orders, 547 units, 76 ICU patients

Appendix B	- Previous Audits of Prescribing or Use of Fresh Frozen Plasma
------------	--

Appendix C - Site Specific Data

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
					No	Anticoagulant Reversal-		
1	5.10-10.00	2.10-5.00	N/A	N/A	bleeding	Coumadin	1	Inappropriate
ite 2								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of	1-2x upper limit of				
1	1.10-1.50	2.10-5.00	normal range	normal range	Bleeding	Massive transfusion	A4	Appropriate
2	1.10-1.50	2.10-5.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriato
2	1.10-1.50	2.10-5.00	nonnarrange		No	Anticoagulant Reversal-	A4	Appropriate
3	5.10-10.00	2.10-5.00	N/A	N/A	bleeding	Coumadin	11	Inappropriate
			Within normal	Within normal				
4	1.10-1.50	1.10-1.50	range Within normal	range Within normal	Bleeding	Surgery	13	Inappropriate
5	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
Ŭ	1110 1100		Within normal	Within normal	Diobaling	Cargory		mappropriate
6	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
-	4 40 4 50	4 40 4 50	Within normal	Within normal	Dissellar	0	10	1
7	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery Anticoagulant Reversal-	13	Inappropriate
8	2.10-5.00	1.60-2.00	N/A	N/A	Bleeding	Coumadin	A1	Appropriate
						Anticoagulant Reversal-		
9	2.10-5.00	1.60-2.00	N/A	N/A	Bleeding	Coumadin	A1	Appropriate
40	4 00 0 00	4 00 0 00	Within normal	N1/A	No	Anticoagulant Reversal-		1
10	1.60-2.00	1.60-2.00	range	N/A	bleeding No	Coumadin	1	Inappropriate
11	1.60-2.00	1.60-2.00	N/A	N/A	bleeding	Surgery	A2	Appropriate
					No			
12	1.60-2.00	1.60-2.00	N/A	N/A	bleeding	Surgery	A2	Appropriate
10	1.60-2.00	1 10 1 50	Within normal	N/A	No bleeding	Anticoagulant Reversal- Unknown	16	Inonpropriate
13	1.00-2.00	1.10-1.50	range	IN/A	No	Anticoagulant Reversal-	10	Inappropriate
14	1.60-2.00	1.10-1.50	N/A	N/A	bleeding	Coumadin	11	Inappropriate
			<u>.</u>					
ite 3					I			
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	2.10-5.00	1.10-1.50	1-2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
	2.10 0.00	1.10 1.00	1-2x upper limit of		No	Anticoagulant Reversal-	7.1	rippiopilate
2	2.10-5.00	1.10-1.50	normal range	N/A	bleeding	Warfarin	11	Inappropriate
ite 4	D 11/2	D	5 5		.			.
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication Anticoagulant Reversal-	Code	Result
1	2.10-5.00	1.10-1.50	N/A	N/A	Bleeding	Coumadin	A1	Appropriate
				1			1	
Site 5	1	1		ſ		ſ		
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
4	1 10 1 50	N1/A	NI/A	NI/A	No	Anticoagulant Reversal-	14	Inconstructor
1	1.10-1.50	N/A	N/A	N/A	bleeding No	Heparin Anticoagulant Reversal-	14	Inappropriate
2	>10.00	N/A	N/A	N/A	bleeding	Coumadin	11	Inappropriate
						Coagulopathy (liver disease,		
3	1.10-1.50	N/A	N/A	N/A	Bleeding	DIC, etc)	13	Inappropriate
4	2 40 5 00	NI/A	NI/A	NI/A	No	Anticoagulant Reversal-	14	Inonnersiet
4	2.10-5.00	N/A	N/A	N/A	bleeding Minor	Coumadin Anticoagulant Reversal-	11	Inappropriate
5	5.10-10.00	2.10-5.00	N/A	N/A	bleeding	Coumadin	A2	Appropriate
-			Within normal	Within normal				
6	1.10-1.50	1.10-1.50	range	range	Bleeding	Massive transfusion	M4	Indeterminat

Site 6								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.10-1.50	N/A	N/A	N/A	Bleeding	Surgery	13	Inappropriate

Site 7

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal	Within normal				
1	1.60-2.00	1.10-1.50	range	range	Bleeding	Surgery	A6	Appropriate
			Within normal	>2x upper limit of	No	Plasma exchange (therapeutic		
2	1.10-1.50	1.10-1.50	range	normal range	bleeding	apheresis)	A5	Appropriate
				Within normal				
3	N/A	1.10-1.50	N/A	range	Bleeding	Surgery	M1	Indeterminate
			Within normal					
4	1.60-2.00	N/A	range	N/A	Bleeding	GI Bleed	A3	Appropriate
			1-2x upper limit of					
5	1.10-1.50	N/A	normal range	N/A	Bleeding	Surgery	A6	Appropriate
			1-2x upper limit of	Within normal				
6	2.10-5.00	1.10-1.50	normal range	range	Bleeding	GI Bleed	A3	Appropriate

Site 8

site o	1						1	
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of	1-2x upper limit of				
1	1.10-1.50	1.10-1.50	normal range	normal range	Unknown	Surgery	M5	Indeterminate
			1-2x upper limit of			Anticoagulant Reversal-		
2	2.10-5.00	1.10-1.50	normal range	N/A	Unknown	Coumadin	M5	Indeterminate
			1-2x upper limit of			Anticoagulant Reversal-		
3	1.60-2.00	N/A	normal range	N/A	Unknown	Coumadin	M5	Indeterminate
				Within normal	No	Anticoagulant Reversal-		
4	1.60-2.00	1.10-1.50	N/A	range	bleeding	Coumadin	11	Inappropriate
				Within normal				
5	N/A	1.10-1.50	N/A	range	Bleeding	Massive transfusion	M4	Indeterminate
			1-2x upper limit of		No	Anticoagulant Reversal-		
6	5.10-10.00	1.10-1.50	normal range	N/A	bleeding	Coumadin	11	Inappropriate

C:	ta	0
.	LC.	7

ite 9		1			1		-	1
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of		No	Anticoagulant Reversal-		
1	5.10-10.00	N/A	normal range	N/A	bleeding	Warfarin	11	Inappropriate
						Coagulopathy (liver disease,		
2	1.60-2.00	1.10-1.50	N/A	N/A	Bleeding	DIC, etc)	A3	Appropriate
			1-2x upper limit of	1-2x upper limit of	No	Coagulopathy (liver disease,		
3	5.10-10.00	2.10-5.00	normal range	normal range	bleeding	DIC, etc)	M3	Indeterminate
			Within normal		Minor	Anticoagulant Reversal-		
4	1.60-2.00	1.10-1.50	range	N/A	bleeding	Coumadin	A1	Appropriate
				1-2x upper limit of	No	Anticoagulant Reversal-		
5	2.10-5.00	1.60-2.00	N/A	normal range	bleeding	Warfarin	l1	Inappropriate
6	2.10-5.00	N/A	N/A	N/A	Unknown	Surgery	M5	Indeterminate

Site 10

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	N/A	1.10-1.50	N/A	1-2x upper limit of normal range	No bleeding	Surgery	М3	Indeterminate
2	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery	A2	Appropriate
3	1.10-1.50	1.10-1.50	>2x upper limit of normal range	Within normal range	Minor bleeding	Surgery	A6	Appropriate
4	1.10-1.50	N/A	1-2x upper limit of normal range	N/A	Bleeding	Surgery	A6	Appropriate
5	1.10-1.50	N/A	1-2x upper limit of normal range	N/A	Minor bleeding	Surgery	A6	Appropriate
6	2.10-5.00	N/A	1-2x upper limit of normal range	N/A	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate
7	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
8	1.60-2.00	1.10-1.50	Within normal range	Within normal range	Minor bleeding	Other Bleed*	A3	Appropriate
9	1.10-1.50	N/A	Within normal range	N/A	Minor bleeding	Surgery	13	Inappropriate

		-	<u>.</u>				-	
10	N/A	1.10-1.50	N/A	1-2x upper limit of normal range	Bleeding	Surgery	A6	Appropriate
11	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Trauma- MVA	A4	Appropriate
12	1.10-1.50	1.10-1.50	Within normal range	Within normal range	Bleeding	Trauma- MVA	13	Inappropriate
13	2.10-5.00	N/A	1-2x upper limit of normal range	N/A	No bleeding	Surgery*- Incarcerated Hernia	A6	Appropriate
14	2.10-5.00	2.10-5.00	>2x upper limit of normal range	>2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
15	2.10-5.00	1.60-2.00	>2x upper limit of normal range	>2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
16	1.60-2.00	1.10-1.50	>2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Massive transfusion	A4	Inappropriate
17	1.60-2.00	1.10-1.50	>2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
18	1.60-2.00	0.50-1.00	>2x upper limit of normal range	>2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
19	1.60-2.00	0.50-1.00	>2x upper limit of normal range	>2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
20	1.60-2.00	0.50-1.00	>2x upper limit of normal range	>2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
21	N/A	0.50-1.00	N/A	>2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
22	N/A	0.50-1.00	N/A	>2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
23	0.50-1.00	N/A	1-2x upper limit of normal range	N/A	Bleeding	Massive transfusion	A4	Appropriate
24	2.10-5.00	N/A	1-2x upper limit of normal range	N/A	Bleeding	Surgery	A6	Appropriate
25	1.60-2.00	1.10-1.50	Within normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
25	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding		A6	
20	N/A	1.60-2.00	N/A	Within normal	Minor	Surgery	A6	Appropriate
			Within normal	range Within normal	bleeding	Surgery		Appropriate
28	1.10-1.50	1.10-1.50	range	range Within normal	Bleeding Minor	Surgery	13	Inappropriate
29	N/A	1.60-2.00	N/A Within normal	range Within normal	bleeding Minor	Miscellaneous*- Burn	A3	Appropriate
30	1.10-1.50	1.10-1.50	range	range	bleeding	Surgery	13	Inappropriate
Site 11 #	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	N/A	Bleeding	Surgery	A6	Appropriate
2	N/A	N/A	N/A	N/A	No bleeding	Miscellaneous*- Familial TTP on regular plasma infusions	A5	Appropriate
3	5.10-10.00	N/A	1-2x upper limit of normal range	N/A	Minor	Anticoagulant Reversal- Warfarin	A1	Appropriate
			1-2x upper limit of normal range	Within normal	Minor	Anticoagulant Reversal-		
4	5.10-10.00 1.10-1.50	1.10-1.50 N/A	Within normal	range N/A	bleeding Minor bleeding	Warfarin Anticoagulant Reversal- Warfarin	A1 13	Appropriate
			range 1-2x upper limit of	Within normal				Inappropriate
6	1.10-1.50	1.10-1.50	normal range	range	Unknown No	Central line placement Plasma exchange (therapeutic	A2	Appropriate
7	N/A	N/A	N/A	N/A	bleeding No	apheresis) Plasma exchange (therapeutic	A5	Appropriate
8	N/A	N/A	N/A Within normal	N/A Within normal	bleeding	apheresis)	A5	Appropriate
9	1.60-2.00	0.50-1.00	range 1-2x upper limit of	range Within normal	Bleeding	GI Bleed	A3	Appropriate
10	1.60-2.00	1.10-1.50	normal range 1-2x upper limit of	range Within normal	Bleeding	Unknown	A3	Appropriate
11	1.60-2.00	1.10-1.50	normal range	range	Bleeding	Liver biopsy	A3	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	2.10-5.00	N/A	1-2x upper limit of normal range	N/A	Unknown	Coagulopathy (liver disease, DIC, etc)	M5	Indeterminat
2	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Unknown	Coagulopathy (liver disease, DIC, etc)	M5	Indeterminat
			1-2x upper limit of			Anticoagulant Reversal-		
3	1.60-2.00	N/A	normal range 1-2x upper limit of	N/A 1-2x upper limit of	Unknown	Unknown	M5	Indeterminat
4	1.60-2.00	1.10-1.50	normal range >2x upper limit of	normal range	Unknown No	Surgery Anticoagulant Reversal-	A6	Appropriate
5	N/A	N/A	normal range 1-2x upper limit of	N/A	bleeding	Heparin Anticoagulant Reversal-	14	Inappropriat
6	2.10-5.00	N/A	normal range	N/A Within normal	Unknown	Coumadin	M5	Indetermina
7	N/A	1.10-1.50	N/A	range	Unknown	Surgery	M2	Indetermina
8	1.60-2.00	N/A	>2x upper limit of normal range	Within normal range	Unknown	Anticoagulant Reversal- Heparin	14	Inappropriat
9	1.60-2.00	N/A	N/A	N/A	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
ite 13								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.10-1.50	1.10-1.50	Within normal range	Within normal range	Unknown	Surgery	13	Inappropriat
2	N/A	N/A	N/A	N/A	Unknown	Miscellaneous*- Low Platelets	M1	Indetermina
3	N/A	N/A	N/A	N/A	No bleeding	Plasma exchange (therapeutic apheresis)	A5	Appropriate
4	N/A	N/A	N/A	N/A	No bleeding	Plasma exchange (therapeutic apheresis)	A5	Appropriate
5	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	No bleeding	Surgery	16	Inappropriat
ite 14								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.60-2.00	N/A	Within normal range	N/A	Bleeding	Volume expansion	A3	Appropriate
2	1.60-2.00	N/A	Within normal range	N/A	Bleeding	Volume expansion	A3	Appropriate
3	2.10-5.00	1.60-2.00	>2x upper limit of normal range	Within normal range	Bleeding	Anticoagulant Reversal- Unknown	A1	Appropriate
4	1.10-1.50	N/A	Within normal range	N/A	No bleeding	Paracentesis	13	Inappropriat
5	2.10-5.00	1.60-2.00	Within normal range	N/A	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriat
6	1.10-1.50	N/A	Within normal range	N/A	Minor bleeding	Anticoagulant Reversal- Coumadin	13	Inappropriat
ite 15	1.10 1.00	10/7	Turigo		biccuirig	Countain	10	mappropriat
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.10-1.50	N/A	Within normal range	N/A	Bleeding	Surgery	13	Inappropriat
2	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	N/A	Unknown	Anticoagulant Reversal- Coumadin	M5	Indetermina
3	2.10-5.00	1.60-2.00	Within normal range	Within normal range	Unknown	Anticoagulant Reversal- Coumadin	11	Inappropria
4	1.60-2.00	1.10-1.50	N/A	N/A	Unknown	Anticoagulant Reversal- Coumadin	M5	Indetermina
	1.10-1.50	1.10-1.50	Within normal range	Within normal range	Bleeding	Surgery	13	Inappropria
5		1.60-2.00	1-2x upper limit of normal range	>2x upper limit of normal range	Unknown	Anticoagulant Reversal- Coumadin	M5	Indetermina
5 6	2.10-5.00					Anticoagulant Reversal-		
	2.10-5.00 1.10-1.50	1.10-1.50	N/A	N/A	Unknown	Coumadin	13	Inappropria
6		1.10-1.50 N/A	N/A N/A	N/A N/A	Unknown Bleeding	Coumadin Coagulopathy (liver disease, DIC, etc) Anticoagulant Reversal-	13 A3	Inappropriat Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
11	N/A	1.10-1.50	N/A	N/A	Unknown	Anticoagulant Reversal- Coumadin	M1	Indeterminate
12	5.10-10.00	N/A	N/A	N/A	Unknown	Anticoagulant Reversal- Warfarin	M5	Indeterminate
21	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	N/A	No bleeding	Anticoagulant Reversal- Coumadin	13	Inappropriate
22	1.10-1.50	N/A	1-2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Warfarin	A3	Appropriate
41	0.50-1.00	N/A	1-2x upper limit of normal range	N/A	Bleeding	Other Bleed*- Vag Bleed in Pregnancy	A3	Appropriate
51	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Minor bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
52	1.60-2.00	N/A	1-2x upper limit of normal range	N/A	Minor bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate

Site 17	•	-	-			T	T	
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
					Minor	Anticoagulant Reversal-		
1	1.60-2.00	N/A	N/A	N/A	bleeding	Unknown	A3	Appropriate
			1-2x upper limit of	Within normal	Minor	Anticoagulant Reversal-		
2	1.10-1.50	1.10-1.50	normal range	range	bleeding	Unknown	A2	Appropriate
					No	Anticoagulant Reversal-		
3	2.10-5.00	N/A	N/A	N/A	bleeding	Unknown	16	Inappropriate
						Other Bleed*- Patient bled 3		
4	1.60-2.00	N/A	N/A	N/A	Bleeding	units of RBCs given in 24 hours	A3	Appropriate
5	N/A	N/A	N/A	N/A	Bleeding	Massive transfusion	M4	Indeterminate
			1-2x upper limit of		No	Coagulopathy (liver disease,		
6	2.10-5.00	N/A	normal range	N/A	bleeding	DIC, etc)	M3	Indeterminate
			1-2x upper limit of			Coagulopathy (liver disease,		
7	1.60-2.00	N/A	normal range	N/A	Bleeding	DIC, etc)	A3	Appropriate
			1-2x upper limit of		Minor	Coagulopathy (liver disease,		
8	5.10-10.00	N/A	normal range	N/A	bleeding	DIC, etc)	A2	Appropriate
			1-2x upper limit of		No			
9	1.60-2.00	N/A	normal range	N/A	bleeding	Surgery	A2	Appropriate
					No	Anticoagulant Reversal-		
10	2.10-5.00	1.60-2.00	N/A	N/A	bleeding	Unknown	16	Inappropriate

Site 18

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
900	1.60-2.00	1.60-2.00	1-2x upper limit of normal range	N/A	No bleeding	Anticoagulant Reversal- Unknown	M3	Indeterminate
901	1.10-1.50	N/A	1-2x upper limit of normal range	N/A	Bleeding	Massive transfusion	A4	Appropriate
902	2.10-5.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
903	1.60-2.00	N/A	1-2x upper limit of normal range	N/A	Bleeding		A3	Appropriate
904	N/A	1.60-2.00	N/A	Within normal range	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
905	2.10-5.00	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
906	2.10-5.00	2.10-5.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Minor bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
907	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Minor bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
908	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	No bleeding	Central line placement	A2	Appropriate
909	1.10-1.50	1.10-1.50	>2x upper limit of normal range	Within normal range	Minor bleeding	Coagulopathy (liver disease, DIC, etc)	A2	Appropriate
910	1.60-2.00	1.60-2.00	1-2x upper limit of normal range	Within normal range	No bleeding	Coagulopathy (liver disease, DIC, etc)	M3	Indeterminate
911	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
912	1.10-1.50	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Minor bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate

			1-2x upper limit of	Within normal		Coagulopathy (liver disease,		
913	1.60-2.00	1.60-2.00	normal range	range	Bleeding	DIC, etc)	A3	Appropriate
			1-2x upper limit of			Coagulopathy (liver disease,		
914	1.10-1.50	N/A	normal range	N/A	Bleeding	DIC, etc)	A2	Appropriate
			Within normal		No			
915	1.60-2.00	N/A	range	N/A	bleeding	Central line placement	A1	Appropriate
			1-2x upper limit of		No	Coagulopathy (liver disease,		
916	1.60-2.00	N/A	normal range	N/A	bleeding	DIC, etc)	M3	Indeterminate
			1-2x upper limit of	1-2x upper limit of	No			
917	1.60-2.00	1.10-1.50	normal range	normal range	bleeding	Image guided therapy	A2	Appropriate
			1-2x upper limit of	1-2x upper limit of		Surgery*- CABG/Valve		
918	2.10-5.00	1.60-2.00	normal range	normal range	Bleeding	Replacement	A3	Appropriate
			1-2x upper limit of		No	Coagulopathy (liver disease,		
919	1.60-2.00	N/A	normal range	N/A	bleeding	DIC, etc)	M3	Indeterminate
			Within normal	>2x upper limit of	No			
920	1.60-2.00	1.10-1.50	range	normal range	bleeding	Cardiac catheterization	A2	Appropriate
			Within normal	Within normal		Coagulopathy (liver disease,		
921	2.10-5.00	1.60-2.00	range	range	Bleeding	DIC, etc)	A3	Appropriate

Site 19

ite 19	-		D DTT			D		–
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of					
1	1.60-2.00	1.10-1.50	normal range	N/A	Bleeding	Surgery	A6	Appropriate
			Within normal	Within normal		Miscellaneous*- Alcohol		
2	1.10-1.50	1.10-1.50	range	range	Bleeding	Withdrawl	13	Inappropriate
			>2x upper limit of	>2x upper limit of				
3	2.10-5.00	1.10-1.50	normal range	normal range	Unknown	Sepsis	M5	Indeterminate
			1-2x upper limit of		No	Anticoagulant Reversal-		
4	2.10-5.00	1.10-1.50	normal range	N/A	bleeding	Coumadin	11	Inappropriate
			>2x upper limit of		No	Anticoagulant Reversal-		
5	1.60-2.00	1.10-1.50	normal range	N/A	bleeding	Heparin	14	Inappropriate
			Within normal			Anticoagulant Reversal-		
6	1.60-2.00	N/A	range	N/A	Bleeding	Heparin	14	Inappropriate

Site 20

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of	Within normal		Coagulopathy (liver disease,		
1	2.10-5.00	1.10-1.50	normal range	range	Bleeding	DIC, etc)	A3	Appropriate
			Within normal	Within normal		Coagulopathy (liver disease,		
2	2.10-5.00	1.60-2.00	range	range	Bleeding	DIC, etc)	A3	Appropriate
			Within normal	Within normal		Coagulopathy (liver disease,		
3	1.10-1.50	1.10-1.50	range	range	Bleeding	DIC, etc)	13	Inappropriate
			Within normal			Coagulopathy (liver disease,		
4	1.60-2.00	N/A	range	N/A	Unknown	DIC, etc)	M5	Indeterminate
			1-2x upper limit of	1-2x upper limit of		Coagulopathy (liver disease,		
5	1.10-1.50	1.10-1.50	normal range	normal range	Bleeding	DIC, etc)	A3	Appropriate
6	N/A	N/A	N/A	N/A	Unknown	Plasma protein deficiency- TTP	A5	Appropriate
			1-2x upper limit of	1-2x upper limit of		Coagulopathy (liver disease,		
7	2.10-5.00	1.60-2.00	normal range	normal range	Bleeding	DIC, etc)	A3	Appropriate
				1-2x upper limit of				
8	N/A	1.10-1.50	N/A	normal range	Unknown	Surgery*- Appendectomy	A6	Appropriate
			1-2x upper limit of	1-2x upper limit of	Minor	Sepsis*- Replacement factors,		
9	1.60-2.00	1.10-1.50	normal range	normal range	bleeding	Sepsis, Renal Failure	A3	Appropriate
			1-2x upper limit of	1-2x upper limit of		Coagulopathy (liver disease,		
10	5.10-10.00	1.60-2.00	normal range	normal range	Bleeding	DIC, etc)*	A3	Appropriate
			1-2x upper limit of					
11	1.60-2.00	N/A	normal range	N/A	Bleeding	GI Bleed	A3	Appropriate
			1-2x upper limit of			Coagulopathy (liver disease,		
12	5.10-10.00	1.60-2.00	normal range	N/A	Bleeding	DIC, etc)*	A3	Appropriate
			1-2x upper limit of	1-2x upper limit of		Coagulopathy (liver disease,		
13	1.10-1.50	1.10-1.50	normal range	normal range	Bleeding	DIC, etc)	13	Inappropriate

Site 21

- 4	5110 21								
	#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
						Minor			
	1	N/A	N/A	N/A	N/A	bleeding	Surgery*- Post-op C-Section	M1	Indeterminate

								D
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
	4 00 0 00	4 00 0 00	1-2x upper limit of	Within normal	No	Other Bleed*- Acute	4.0	A
1	1.60-2.00	1.60-2.00	normal range	range	bleeding	Hydrocephalus Thalamic Bleed	A3	Appropriate
			4.0	Mith is a second	NI-	Other Bleed*- Acute		
2	4 00 0 00	4 00 0 00	1-2x upper limit of	Within normal	No	Hydrocephalus Thalamic	4.0	A
2	1.60-2.00	1.60-2.00	normal range	range	bleeding	Bleed- Angio Miscellaneous*- Renal Failure-	A3	Appropriate
0	4 40 4 50		Within normal		Dissilian		10	
3	1.10-1.50		range	4 Ou une en limit of	Bleeding	Spinal Tap	13	Inappropriate
4	4 00 0 00	1 40 4 50	1-2x upper limit of	1-2x upper limit of	Distriction	0	4.0	A
	1.60-2.00	1.10-1.50	normal range	normal range	Bleeding	Surgery	A6	Appropriate
F	4 00 0 00	4 40 4 50	1-2x upper limit of	1-2x upper limit of	Dissilian	Current	10	A
5	1.60-2.00	1.10-1.50	normal range	normal range	Bleeding	Surgery	A6	Appropriate
6	N1/A	1 40 4 50	N1/A	Within normal	Dissilian	Current	M2	
7	N/A	1.10-1.50	N/A	range	Bleeding	Surgery Surgery*- Bilary Obstruction-	IVIZ	Indeterminat
	N/A	N/A	N/A	N/A	Unknown	TIPS revision	M1	Indeterminat
	IN/A	IN/A	>2x upper limit of	1-2x upper limit of	UNKNOWN	Drain/Line Insertion*- arterial		mueterminat
8	2 10 5 00	1.60-2.00	normal range	normal range	Bleeding	line & adb tap for ascites	A2	Appropriato
0	2.10-5.00	1.60-2.00	Within normal	1-2x upper limit of	Dieeding	line & add tap for ascites	AZ	Appropriate
9	1.60-2.00	2.10-5.00		normal range	Bleeding	Surgery	A6	Appropriato
9	1.60-2.00	2.10-5.00	range 1-2x upper limit of	Within normal	Dieeulity	Surgery	AO	Appropriate
10	2.10-5.00	1 60 2 00			Bleeding	Surger (10	Annrantiata
	2.10-5.00	1.60-2.00	normal range	range Within normal	No	Surgery Other Bleed*- SAH- Procedure	A6	Appropriate
11	2 10 5 00	1.10-1.50	1-2x upper limit of		-	LP	A2	Annronrioto
	2.10-5.00	1.10-1.50	normal range	range	bleeding	Drain/Line Insertion*- Liver	AZ	Appropriate
12	N/A	N/A	N/A	N/A	Minor bleeding	failure	M1	Indeterminet
	IN/A	IN/A	1-2x upper limit of	IN/A	bleeding	lanure	IVII	Indeterminat
13	2 10 5 00	N/A		N/A	Dlaading	Concio	10	Appropriate
	2.10-5.00	IN/A	normal range Within normal	Within normal	Bleeding	Sepsis	A3	Appropriate
14	1 60 2 00	1 10 1 50			-	Surger (A6	Annronriete
14	1.60-2.00	1.10-1.50	range	range	bleeding	Surgery	Ab	Appropriate
45	4 00 0 00	4 00 0 00	1-2x upper limit of normal range	1-2x upper limit of normal range	Dissilian	Coordinations the state of Failure	4.0	A
15	1.60-2.00	1.60-2.00	nonnai range	nonnarrange	Bleeding	Coagulopathy*- Liver Failure Drain/Line Insertion*- Acute	A3	Appropriate
16 17			Within normal	Within normal	Minor			
	1 60 2 00	1 60 2 00	Within normal	Within normal	Minor	Bilary Colic- percutaneous	A2	Appropriato
	1.60-2.00	1.60-2.00	range 1-2x upper limit of	range	bleeding Minor	drain line insertion Drain/Line Insertion*- Removal	AZ	Appropriate
	2 10 5 00	N1/A		N/A			10	Appropriate
	2.10-5.00	N/A	normal range	IN/A	bleeding	of percutaneous abscess drain	A2	Appropriate
10	1.10-1.50	N/A	Within normal	N/A	Minor bleeding	Drain/Line Insertion*- Removal of percutaneous abscess drain	12	Inonpropriate
18	1.10-1.50	IN/A	range Within normal	Within normal	bieeding	or percutarieous abscess drain	13	Inappropriate
19	1.60-2.00	1.60-2.00			Bleeding	Surgen	A6	Appropriato
	1.00-2.00	1.00-2.00	range Within normal	range 1-2x upper limit of	Dieeulity	Surgery	AO	Appropriate
20	2.10-5.00	2.10-5.00		normal range	Bleeding	Surgery	A6	Appropriate
	2.10-5.00	2.10-5.00	range	Within normal	Dieeulity	Surgery	AU	Appropriate
21	N/A	1.10-1.50	N/A		Bleeding	Surgery	M1	Indeterminet
21	N/A	1.10-1.50	1-2x upper limit of	range Within normal	Dieeulity	Surgery		Indeterminat
22	1 60 2 00	1 10 1 50			Dlaading	CI Blood* Conoin	10	Appropriato
22	1.60-2.00	1.10-1.50	normal range	range	Bleeding	GI Bleed*- Sepsis	A3	Appropriate
^ 2	1 10 1 50	1.10-1.50	>2x upper limit of normal range	Within normal	Bleeding	Surgery*- Post cardiovascular	A3	Appropriate
23	1.10-1.50	1.10-1.50	0	range 1-2x upper limit of	Dieeding	surgery <24 hrs Miscellaneous*- Heart failure-	AS	Appropriate
04	1	1 60 2 00	1-2x upper limit of		Bleeding	Trach	A3	Appropriate
24	2 10 5 00		normal range	normal range				Appropriate
24	2.10-5.00	1.60-2.00	normal range	normal range	Dieeulity		AS	
24	2.10-5.00	1.60-2.00		normal range		Drain/Line Insertion*-	AJ	
			Within normal		No	Drain/Line Insertion*- Pacemaker problem- lead		Appropriato
24 25	2.10-5.00	N/A	Within normal range	N/A	No bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning	A3 A2	Appropriate
25	2.10-5.00	N/A	Within normal range Within normal	N/A Within normal	No bleeding Minor	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain	A2	•••
			Within normal range Within normal range	N/A Within normal range	No bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion		•••
25 26	2.10-5.00 1.10-1.50	N/A 1.10-1.50	Within normal range Within normal range 1-2x upper limit of	N/A Within normal range 1-2x upper limit of	No bleeding Minor bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral	A2 13	Inappropriate
25	2.10-5.00	N/A	Within normal range Within normal range 1-2x upper limit of normal range	N/A Within normal range 1-2x upper limit of normal range	No bleeding Minor	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency	A2	•••
25 26 27	2.10-5.00 1.10-1.50 2.10-5.00	N/A 1.10-1.50 2.10-5.00	Within normal range Within normal range 1-2x upper limit of normal range Within normal	N/A Within normal range 1-2x upper limit of normal range Within normal	No bleeding Minor bleeding Bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency Other Bleed*- ACS & CHF	A2 13 A3	Inappropriate
25 26	2.10-5.00 1.10-1.50	N/A 1.10-1.50	Within normal range Within normal range 1-2x upper limit of normal range	N/A Within normal range 1-2x upper limit of normal range Within normal range	No bleeding Minor bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency	A2 13	Inappropriate
25 26 27 28	2.10-5.00 1.10-1.50 2.10-5.00 1.10-1.50	N/A 1.10-1.50 2.10-5.00 1.10-1.50	Within normal range Within normal range 1-2x upper limit of normal range Within normal range	N/A Within normal range 1-2x upper limit of normal range Within normal range Within normal	No bleeding Minor bleeding Bleeding Bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency Other Bleed*- ACS & CHF (cranial bleed)	A2 13 A3 13	Inappropriate Appropriate Inappropriate
25 26 27	2.10-5.00 1.10-1.50 2.10-5.00	N/A 1.10-1.50 2.10-5.00	Within normal range Within normal range 1-2x upper limit of normal range Within normal	N/A Within normal range 1-2x upper limit of normal range Within normal range Within normal range	No bleeding Minor bleeding Bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency Other Bleed*- ACS & CHF	A2 13 A3	Inappropriate Appropriate
25 26 27 28 29	2.10-5.00 1.10-1.50 2.10-5.00 1.10-1.50 1.10-1.50	N/A 1.10-1.50 2.10-5.00 1.10-1.50 1.60-2.00	Within normal range Within normal range 1-2x upper limit of normal range Within normal range N/A	N/A Within normal range 1-2x upper limit of normal range Within normal range Within normal range Within normal	No bleeding Minor bleeding Bleeding Bleeding Bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency Other Bleed*- ACS & CHF (cranial bleed) Surgery	A2 13 A3 13 A6	Inappropriate Appropriate Inappropriate Appropriate
25 26 27 28	2.10-5.00 1.10-1.50 2.10-5.00 1.10-1.50	N/A 1.10-1.50 2.10-5.00 1.10-1.50	Within normal range Within normal range 1-2x upper limit of normal range Within normal range N/A N/A	N/A Within normal range 1-2x upper limit of normal range Within normal range Within normal range Within normal range	No bleeding Minor bleeding Bleeding Bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency Other Bleed*- ACS & CHF (cranial bleed)	A2 13 A3 13	Inappropriate Appropriate Inappropriate Appropriate
25 26 27 28 29 30	2.10-5.00 1.10-1.50 2.10-5.00 1.10-1.50 1.10-1.50 N/A	N/A 1.10-1.50 2.10-5.00 1.10-1.50 1.60-2.00 1.10-1.50	Within normal range Within normal range 1-2x upper limit of normal range Within normal range N/A N/A Within normal	N/A Within normal range 1-2x upper limit of normal range Within normal range Within normal range Within normal range Within normal range	No bleeding Minor bleeding Bleeding Bleeding Bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency Other Bleed*- ACS & CHF (cranial bleed) Surgery Surgery	A2 13 A3 13 A6 M2	Inappropriate Appropriate Inappropriate Appropriate Indeterminat
25 26 27 28 29	2.10-5.00 1.10-1.50 2.10-5.00 1.10-1.50 1.10-1.50	N/A 1.10-1.50 2.10-5.00 1.10-1.50 1.60-2.00	Within normal range Within normal range 1-2x upper limit of normal range Within normal range N/A N/A	N/A Within normal range 1-2x upper limit of normal range Within normal range Within normal range Within normal range	No bleeding Minor bleeding Bleeding Bleeding Bleeding	Drain/Line Insertion*- Pacemaker problem- lead repositioning Surgery*- Post Wipple- drain insertion Miscellaneous*- mitral insufficiency Other Bleed*- ACS & CHF (cranial bleed) Surgery	A2 13 A3 13 A6	Inappropriate Appropriate Inappropriate

33	N/A	1.10-1.50	N/A	Within normal range	Bleeding	Surgery	M2	Indeterminate
34	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery*- Post surgery <24 hrs	A6	Appropriate
35	2.10-5.00	2.10-5.00	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery*- returning to surgery	A6	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal	Within normal				
1	0.50-1.00	1.10-1.50	range	range	Bleeding	Surgery	12	Inappropriate
~	N1/A	4 40 4 50	N1/A	Within normal	Dissilias	Current .	140	la determinate
2	N/A	1.10-1.50	N/A 1-2x upper limit of	range	Bleeding	Surgery	M2	Indeterminate
3	2.10-5.00	N/A	normal range	N/A	Bleeding	GI Bleed*- Perforated bowel	A3	Appropriate
5	2.10-5.00	IN/A	1-2x upper limit of	Within normal	Dieeulity	Gi bleed - Fellolated bowel	AJ	Appropriate
4	2.10-5.00	1.10-1.50	normal range	range	Bleeding	GI Bleed*	A3	Appropriate
	2.10 0.00	1110 1.00	normarrango	Within normal	Dioballig	01 21000	7.0	rippropriato
5	N/A	1.60-2.00	N/A	range	Bleeding	GI Bleed*	A3	Appropriate
			Within normal	Within normal	Ŭ	Surgery*- Perforated bowel		
6	1.60-2.00	1.60-2.00	range	range	Bleeding	post-op	A6	Appropriate
					Ŭ	Drain/Line Insertion*- Query		
			>2x upper limit of	1-2x upper limit of		Pulmonary Edema- line		
7	2.10-5.00	2.10-5.00	normal range	normal range	Bleeding	insertion	A2	Appropriate
			1-2x upper limit of	1-2x upper limit of				
8	1.10-1.50	1.10-1.50	normal range	normal range	Bleeding	Surgery	A6	Appropriate
			Within normal	Within normal		Drain/Line Insertion*-		
9	2.10-5.00	1.10-1.50	range	range	Bleeding	Percutaneous line insertion	A2	Appropriate
			Within normal		No	Drain/Line Insertion*- Post		
10	1.10-1.50	N/A	range	N/A	bleeding	procutaneous line insertion	13	Inappropriate
			1-2x upper limit of	Within normal				
11	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Surgery	A6	Appropriate
			Within normal	Within normal				
12	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
40	4 40 4 50	4 40 4 50	1-2x upper limit of	Within normal	Distriction	Ourset Destaurs of her	4.0	A
13	1.10-1.50	1.10-1.50	normal range Within normal	range	Bleeding	Surgery*- Post surgery <24 hrs Thoracentesis*- Pericardial	A6	Appropriate
14	1.10-1.50	N/A		N/A	Unknown	centesis	13	Inonproprioto
14	1.10-1.50	IN/A	range 1-2x upper limit of	Within normal	UNKNOWN	Centesis	13	Inappropriate
15	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Surgery	A6	Appropriate
15	1.10-1.50	1.10-1.50	1-2x upper limit of	Within normal	Minor	Surgery*- Diverticulitis	AU	Appropriate
16	1.60-2.00	1.10-1.50	normal range	range	bleeding	colectomy	A6	Appropriate
10	1.00 2.00	1.10 1.00	Within normal	Within normal	biccuirig		/.0	rippiopilate
17	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
	1.10 1.00	1110 1.00	lange	Within normal	Dioballig		10	mappropriato
18	N/A	1.10-1.50	N/A	range	Bleeding	Surgery	M2	Indeterminate
			1-2x upper limit of	1-2x upper limit of	No	Anticoagulant Reversal-		
19	2.10-5.00	1.60-2.00	normal range	normal range	bleeding	Warfarin	11	Inappropriate
-			>2x upper limit of	1-2x upper limit of	J			
20	1.60-2.00	1.10-1.50	normal range	normal range	Bleeding	Surgery	A6	Appropriate
			1-2x upper limit of	Ŭ	Ŭ			
21	1.10-1.50	N/A	normal range	N/A	Bleeding	Surgery*- Post surgery <24 hrs	A6	Appropriate
						Drain/Line Insertion*- Acute		
			1-2x upper limit of	1-2x upper limit of		Renal Failure- catheter		
22	2.10-5.00	2.10-5.00	normal range	normal range	Bleeding	insertion	A2	Appropriate
			>2x upper limit of	>2x upper limit of				
23	2.10-5.00	2.10-5.00	normal range	normal range	Bleeding	GI Bleed*	A3	Appropriate
			>2x upper limit of					
24	2.10-5.00	N/A	normal range	N/A	Bleeding	GI Bleed*	A3	Appropriate

#	Pre-IN	IR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
				Within normal	Within normal		Other Bleed*- presumed		
	1 1.60-2	2.00	1.10-1.50	range	range	Bleeding	varicele bleeding	A3	Appropriate

Site 25								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.10-1.50	2.10-5.00	Within normal range	1-2x upper limit of normal range	Unknown	Surgery*- Ruptured Spleen	A3	Appropriate
2	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
3	2.10-5.00	N/A	Within normal range	N/A	Bleeding	Other Bleed*- Subdural Hematoma	A3	Appropriate
4	5.10-10.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	GI Bleed*	A3	Appropriate
5	2.10-5.00	2.10-5.00	1-2x upper limit of normal range	1-2x upper limit of normal range	No bleeding	Miscellaneous*- Pain in Mid Back	16	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of	1-2x upper limit of				
1	1.10-1.50	1.10-1.50	normal range	normal range	Bleeding	Surgery	A6	Appropriate
			1-2x upper limit of	Within normal	Minor			
2	1.60-2.00	1.10-1.50	normal range	range	bleeding	Surgery	A6	Appropriate
			Within normal	Within normal	Minor			
3	0.50-1.00	1.10-1.50	range	range	bleeding	Surgery	12	Inappropriate
			1-2x upper limit of		Minor			
4	1.60-2.00	N/A	normal range	N/A	bleeding	Sepsis*- AML, Septic Shock	A3	Appropriate
						Surgery*- Acute hemorrhagic		
			>2x upper limit of	1-2x upper limit of		shock secondary to		
5	2.10-5.00	1.60-2.00	normal range	normal range	Bleeding	cephalohematoma	A3	Appropriate

ite 27								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	2.10-5.00	2.10-5.00	1-2x upper limit of normal range	N/A	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate
2	N/A	N/A	N/A	N/A	Minor bleeding	Anticoagulant Reversal- Coumadin	M1	Indeterminate
3	1.10-1.50	1.10-1.50	Within normal range	Within normal range	No bleeding	Volume expansion	15	Inappropriate
4	2.10-5.00	1.10-1.50	N/A	N/A	Bleeding	Massive transfusion	A4	Appropriate
5	0.50-1.00	1.10-1.50	N/A	Within normal range	Bleeding	Surgery	12	Inappropriate
6	2.10-5.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
7	1.10-1.50	1.60-2.00	Within normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
8	1.10-1.50	1.10-1.50	Within normal range	Within normal range	Bleeding	Surgery	13	Inappropriate
9	1.60-2.00	2.10-5.00	Within normal range	1-2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
10	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	N/A	Bleeding	Surgery	A6	Appropriate
11		1.10-1.50	N/A	Within normal range	Bleeding	Surgery	M2	Indeterminate
12	1.10-1.50	N/A	N/A	N/A	Bleeding	Surgery	13	Inappropriate
13	5.10-10.00	N/A	>2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
14	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal			Coagulopathy (liver disease,		
1	1.60-2.00	N/A	range	N/A	Bleeding	DIC, etc)	A3	Appropriate
			Within normal					
2	2.10-5.00	N/A	range	N/A	Bleeding	Fine Needle aspirate	A2	Appropriate
			Within normal					
3	1.60-2.00	N/A	range	N/A	Bleeding	Massive transfusion	A4	Appropriate
			>2x upper limit of					
4	1.10-1.50	N/A	normal range	N/A	Bleeding	Massive transfusion	A4	Appropriate
			>2x upper limit of		No	Anticoagulant Reversal-		
5	>10.00	1.10-1.50	normal range	N/A	bleeding	Coumadin	11	Inappropriate
			Within normal	Within normal				
6	2.10-5.00	1.60-2.00	range	range	Bleedina	Surgery*- Repeat C-Section	A6	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	5.10-10.00	N/A	1-2x upper limit of normal range	N/A	No bleeding	Anticoagulant Reversal- Warfarin	11	Inappropriate
2	2.10-5.00	N/A	Within normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
3	5.10-10.00	N/A	>2x upper limit of normal range	N/A	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate
4	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate
5	1.10-1.50	1.10-1.50	Within normal range	N/A	No bleeding	Coagulopathy (liver disease, DIC, etc)	13	Inappropriate
6	1.60-2.00	N/A	Within normal range	N/A	No bleeding	Coagulopathy (liver disease, DIC, etc)	16	Inappropriate
7	1.60-2.00	N/A	N/A	N/A	No bleeding	Coagulopathy (liver disease, DIC, etc)	16	Inappropriate
8	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	N/A	No bleeding	Coagulopathy (liver disease, DIC, etc)	16	Inappropriate
9	1.60-2.00	N/A	N/A	N/A	No bleeding	Coagulopathy (liver disease, DIC, etc)	16	Inappropriate
10	1.60-2.00	1.60-2.00	Within normal range	N/A	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate

Site 30

Sile SU								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			>2x upper limit of		No	Miscellaneous*- Subacute		
1	5.10-10.00	N/A	normal range	N/A	bleeding	bowel obstruction	16	Inappropriate
						GI Bleed*- Perforated viscous/		
					Minor	Ruptured diverticuli/ Bloody		
2	2.10-5.00	1.60-2.00	N/A	N/A	bleeding	stool	A3	Appropriate
					No	Miscellaneous*- Pancreatitis/		
3	2.10-5.00	N/A	N/A	N/A	bleeding	Cholecystitis	16	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	5.10-10.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
2	N/A	1.10-1.50	N/A	Within normal range	Bleeding	Surgery*- Radical Prostatectomy	M2	Indeterminate
3	1.10-1.50	1.10-1.50	N/A	Within normal range	No bleeding	Anticoagulant Reversal- Coumadin	13	Inappropriate
4	>10.00	2.10-5.00	N/A	N/A	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
5	N/A	1.10-1.50	N/A	Within normal range	Unknown	Paracentesis	M2	Indeterminate
6	2.10-5.00	N/A	Within normal range	N/A	Unknown	Coagulopathy (liver disease, DIC, etc)	M5	Indeterminate

Site 32								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Unknown	Anticoagulant Reversal- Warfarin	M5	Indeterminate
2	1.10-1.50	N/A	N/A	N/A	Unknown	Image guided therapy	13	Inappropriate
3	5.10-10.00	1.10-1.50	1-2x upper limit of normal range	N/A	Bleeding	Massive transfusion	A4	Appropriate
4	1.60-2.00	1.10-1.50	Within normal range	Within normal range	Unknown	Anticoagulant Reversal- Warfarin	M5	Indeterminate
5	2.10-5.00	2.10-5.00	Within normal range	Within normal range	Bleeding	Massive transfusion	A4	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Unknown	Surgery*- Bowel Resection	A2	Appropriate
2	1.60-2.00	N/A	1-2x upper limit of normal range	N/A	Unknown	Leukemia*- Leukemia receiving alternative treatment	M5	Indeterminate
3	1.60-2.00	1.10-1.50	Within normal range	Within normal range	Bleeding	Surgery*- Surgical complications	A6	Appropriate
4	1.10-1.50	N/A	N/A	N/A	Unknown	Unknown*- Not indicated	13	Inappropriate

Site 34								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
				Within normal				
1	N/A	1.10-1.50	N/A	range	Bleeding	Surgery	M2	Indeterminate
			Within normal	Within normal				
2	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
			Within normal		No			
3	1.60-2.00	1.60-2.00	range	N/A	bleeding	Thoracentesis	A2	Appropriate
					No			
4	1.60-2.00	N/A	N/A	N/A	bleeding	Thoracentesis	A2	Appropriate
				Within normal				
5	N/A	1.10-1.50	N/A	range	Bleeding	Surgery	M2	Indeterminate
			Within normal	Within normal				
6	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
			Within normal	Within normal				
7	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
			Within normal					
8	1.10-1.50	N/A	range	N/A	Bleeding	Surgery	13	Inappropriate
					No	GI Bleed*- Endoscopy (upper		
9	1.60-2.00	N/A	N/A	N/A	bleeding	UGIB)	A2	Appropriate
			Within normal					
10	2.10-5.00	N/A	range	N/A	Bleeding	Other Bleed*- Rt. Parietal bleed	A3	Appropriate
						Miscellaneous*- 1 unit		
						requested to replace 1 unit in		
						case 010 where only 10 ml		
11	N/A	N/A	N/A	N/A	Bleeding	given as bag was leaking	M1	Indeterminate
			Within normal		No	Coagulopathy (liver disease,		
12	1.60-2.00	1.10-1.50	range	N/A	bleeding	DIC, etc)	16	Inappropriate
13	N/A	N/A	N/A	N/A	Unknown	Surgery	M1	Indeterminate
			Within normal	Within normal		Anticoagulant Reversal-		
14	1.10-1.50	1.10-1.50	range	range	Bleeding	Heparin	14	Inappropriate
			1-2x upper limit of	1-2x upper limit of	J	Anticoagulant Reversal-		
15	1.10-1.50	1.10-1.50	normal range	normal range	Bleeding	Heparin	14	Inappropriate
-			Within normal	Within normal	No			
16	1.10-1.50	1.10-1.50	range	range	bleeding	Sepsis*- Ruptured gallbladder	13	Inappropriate
			Within normal	Within normal	No	<u> </u>		
17	1.10-1.50	1.10-1.50	range	range	bleeding	Leukemia*- Acute Leukemia	13	Inappropriate
			Within normal	Within normal				
18	1.10-1.50	1.10-1.50	range	range	Bleeding	Sepsis*- Ruptured gallbladder	13	Inappropriate
. •			Within normal	Within normal				
19	1.60-2.00	1.10-1.50	range	range	Bleeding	Surgery	A6	Appropriate
			1-2x upper limit of	Within normal	g			
20	1.60-2.00	1.10-1.50	normal range	range	Bleeding	Other Bleed*	A3	Appropriate
20			Within normal	Within normal	Dioballig			
21	1.10-1.50	1.10-1.50	range	range	Bleeding	Other Bleed*	13	Inappropriate
<u> </u>	1.10-1.00	1.10-1.00	lange	lange	Diccurry			mappiopnate

			Within normal	Within normal	No	Coagulopathy (liver disease,		
22	1.10-1.50	1.10-1.50	range	range	bleeding	DIC, etc)	13	Inappropriate
			1-2x upper limit of	1-2x upper limit of		Anticoagulant Reversal-		
23	1.60-2.00	1.10-1.50	normal range	normal range	Bleeding	Warfarin	A1	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	Minor bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
2	1.60-2.00	N/A	1-2x upper limit of normal range	N/A	Minor bleeding	Surgery	A6	Appropriate
3	1.60-2.00	1.10-1.50	Within normal range	N/A	No bleeding	Surgery*- Removal massive lymph nodes	A2	Appropriate
4	1.10-1.50	1.10-1.50	Within normal range	1-2x upper limit of normal range	Bleeding	Massive transfusion	A4	Appropriate
5	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Massive transfusion	A4	Appropriate
6	1.60-2.00	1.10-1.50	Within normal range	Within normal range	No bleeding	Sepsis	16	Inappropriat
7	1.60-2.00	N/A	Within normal range	N/A	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
8	1.10-1.50	N/A	Within normal range	N/A	Unknown	Surgery*- pre-surgery	13	Inappropriat
9	1.10-1.50	N/A	Within normal range	N/A	Bleeding	Massive transfusion	M4	Indetermina
10	1.10-1.50	1.10-1.50	Within normal range	Within normal range	Bleeding	Massive transfusion	M4	Indeterminat
11	1.60-2.00	1.10-1.50	Within normal range	Within normal range	No bleeding	Coagulopathy (liver disease, DIC, etc)	16	Inappropriat

Site 36

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
2	1.60-2.00	N/A	Within normal range	N/A	Bleeding	Massive transfusion	A4	Appropriate
3	1.10-1.50	1.10-1.50	N/A	N/A	No bleeding	Surgery*- CA pancreas/liver	13	Inappropriate
4	5.10-10.00	2.10-5.00	N/A	N/A	No bleeding	Anticoagulant Reversal- Unknown	11	Inappropriate
5	2.10-5.00	1.60-2.00	N/A	N/A	No bleeding	Anticoagulant Reversal- Unknown	11	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.60-2.00	N/A	N/A	N/A	Unknown	Surgery	A6	Appropriate
2	1.60-2.00	N/A	N/A	N/A	Unknown	Surgery	A6	Appropriate
3	1.60-2.00	N/A	N/A	N/A	Unknown	Sepsis	M6	Indeterminate
4	1.60-2.00	N/A	N/A	N/A	Unknown	Sepsis	M5	Indeterminate
5	1.60-2.00	N/A	1-2x upper limit of normal range	N/A	Minor bleeding	GI Bleed	A3	Appropriate
6	N/A	N/A	N/A	N/A	Minor bleeding	GI Bleed	M1	Indeterminate
7	>10.00	1.60-2.00	>2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Unknown	A1	Appropriate
8	2.10-5.00	N/A	N/A	N/A	Unknown	Anticoagulant Reversal- Coumadin	M5	Indeterminate
9	1.10-1.50	N/A	N/A	N/A	Minor bleeding	Sepsis	13	Inappropriate
10	5.10-10.00	N/A	1-2x upper limit of normal range	N/A	Minor bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.10-1.50	N/A	1-2x upper limit of normal range	N/A	Bleeding	Massive transfusion	A4	Appropriate
2	2.10-5.00	1.10-1.50	>2x upper limit of normal range	Within normal range	Minor bleeding	Paracentesis	A2	Appropriate
3	>10.00	2.10-5.00	>2x upper limit of normal range	1-2x upper limit of normal range	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate
4	1.60-2.00	1.60-2.00	1-2x upper limit of normal range	>2x upper limit of normal range	Minor bleeding	Paracentesis	A2	Appropriate
5	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	N/A	Minor bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
6	5.10-10.00	N/A	1-2x upper limit of normal range	N/A	Minor bleeding	Anticoagulant Reversal- Warfarin	A1	Appropriate
7	1.60-2.00	1.10-1.50	N/A	N/A	No bleeding	Anticoagulant Reversal- Warfarin	11	Inappropriate
8	1.10-1.50	N/A	>2x upper limit of normal range	N/A	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
9	2.10-5.00	N/A	N/A	N/A	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
					No			
1	1.60-2.00	1.10-1.50	N/A	N/A	bleeding	Surgery	A2	Appropriate
					No	Coagulopathy (liver disease,		
2	1.60-2.00	N/A	N/A	N/A	bleeding	DIC, etc)	16	Inappropriate
					No			
3	1.60-2.00	1.10-1.50	N/A	N/A	bleeding	Surgery	A2	Appropriate
			1-2x upper limit of	Within normal		Anticoagulant Reversal-		
4	>10.00	1.10-1.50	normal range	range	Bleeding	Coumadin	A1	Appropriate
5	1.10-1.50	N/A	N/A	N/A	Bleeding	Massive transfusion	M4	Indeterminate
			Within normal	Within normal	No			
6	1.60-2.00	1.10-1.50	range	range	bleeding	Surgery	A2	Appropriate

Site 40

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
					Minor			
1	>10.00	2.10-5.00	N/A	N/A	bleeding	Image guided therapy	A2	Appropriate
			1-2x upper limit of					
2	2.10-5.00	1.10-1.50	normal range	N/A	Bleeding	Image guided therapy	A2	Appropriate
			1-2x upper limit of					
3	>10.00	2.10-5.00	normal range	N/A	Bleeding	Image guided therapy	A2	Appropriate
			Within normal		Minor			
4	0.50-1.00	N/A	range	N/A	bleeding	Image guided therapy	12	Inappropriate
			1-2x upper limit of					
5	2.10-5.00	N/A	normal range	N/A	Unknown	Miscellaneous*- Stroke	M5	Indeterminate
				Within normal		Anticoagulant Reversal-		
6	5.10-10.00	1.60-2.00	N/A	range	Bleeding	Coumadin	A1	Appropriate

#		Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
				Within normal					
	1	1.60-2.00	N/A	range	N/A	Bleeding	Massive transfusion	A4	Appropriate
				Within normal					
	2	1.60-2.00	1.60-2.00	range	N/A	Bleeding	Massive transfusion	A4	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of		Minor			
1	5.10-10.00	N/A	normal range	N/A	bleeding	Other Bleed*- Hematuria	A3	Appropriate
					Minor			
2	5.10-10.00	N/A	N/A	N/A	bleeding	Other Bleed*- Wound Bleeding	A3	Appropriate
			1-2x upper limit of		No	Anticoagulant Reversal-		
3	5.10-10.00	N/A	normal range	N/A	bleeding	Unknown	11	Inappropriate
			1-2x upper limit of		No	Anticoagulant Reversal-		
4	>10.00	2.10-5.00	normal range	N/A	bleeding	Unknown	11	Inappropriate
			1-2x upper limit of	1-2x upper limit of	No			
5	1.10-1.50	1.10-1.50	normal range	normal range	bleeding	Surgery	A2	Appropriate
			>2x upper limit of		No	Anticoagulant Reversal-		
6	>10.00	N/A	normal range	N/A	bleeding	Unknown	11	Inappropriate
			>2x upper limit of		Minor	Anticoagulant Reversal-		
7	>10.00	N/A	normal range	N/A	bleeding	Unknown	A1	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal	Within normal				
1	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriate
			Within normal	Within normal				
2	2.10-5.00	1.10-1.50	range	range	Bleeding	Surgery	A6	Appropriate
			Within normal					
3	1.10-1.50	N/A	range	N/A	Bleeding	Surgery	13	Inappropriate
			1-2x upper limit of	1-2x upper limit of	No	Anticoagulant Reversal-		
4	1.10-1.50	1.10-1.50	normal range	normal range	bleeding	Heparin	14	Inappropriate
				1-2x upper limit of	No	Anticoagulant Reversal-		
5	>10.00	2.10-5.00	N/A	normal range	bleeding	Warfarin	11	Inappropriate
			Within normal		Minor	Coagulopathy (liver disease,		
6	1.10-1.50	N/A	range	N/A	bleeding	DIC, etc)	13	Inappropriate
			Within normal	1-2x upper limit of				
7	1.10-1.50	1.10-1.50	range	normal range	Bleeding	Surgery	A6	Appropriate
			1-2x upper limit of			Coagulopathy (liver disease,		
8	1.10-1.50	N/A	normal range	N/A	Bleeding	DIC, etc)	A3	Appropriate

Site 44

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
					No	Surgery*- Pre-op Splenectomy		
1	N/A	N/A	N/A	N/A	bleeding	order	M1	Indeterminate
			>2x upper limit of		No	Anticoagulant Reversal-		
2	1.60-2.00	N/A	normal range	N/A	bleeding	Heparin	14	Inappropriate
			1-2x upper limit of	1-2x upper limit of		Coagulopathy (liver disease,		
3	2.10-5.00	1.10-1.50	normal range	normal range	Bleeding	DIC, etc)	A3	Appropriate
			>2x upper limit of			Coagulopathy (liver disease,		
4	5.10-10.00	N/A	normal range	N/A	Bleeding	DIC, etc)	A3	Appropriate
			>2x upper limit of	1-2x upper limit of	Minor	Anticoagulant Reversal-		
5	>10.00	1.60-2.00	normal range	normal range	bleeding	Warfarin	A1	Appropriate
				1-2x upper limit of	No			
6	1.60-2.00	1.10-1.50	N/A	normal range	bleeding	Surgery	A2	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of	1-2x upper limit of	Minor	Anticoagulant Reversal-		
1	5.10-10.00	2.10-5.00	normal range	normal range	bleeding	Coumadin	A1	Appropriate
			1-2x upper limit of		No	Anticoagulant Reversal-		
2	2.10-5.00	1.60-2.00	normal range	N/A	bleeding	Coumadin	11	Inappropriate
			>2x upper limit of		Minor	Anticoagulant Reversal-		
3	5.10-10.00	N/A	normal range	N/A	bleeding	Coumadin	A1	Appropriate
			1-2x upper limit of		Minor	Anticoagulant Reversal-		
4	2.10-5.00	N/A	normal range	N/A	bleeding	Coumadin	A1	Appropriate
			1-2x upper limit of		No	Anticoagulant Reversal-		
5	1.60-2.00	1.10-1.50	normal range	N/A	bleeding	Coumadin	11	Inappropriate
			1-2x upper limit of		No	Anticoagulant Reversal-		
6	2.10-5.00	1.60-2.00	normal range	N/A	bleeding	Coumadin	11	Inappropriate
			Within normal		Minor	Anticoagulant Reversal-		
7	5.10-10.00	N/A	range	N/A	bleeding	Coumadin	A1	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.10-1.50	N/A	1-2x upper limit of normal range	1-2x upper limit of normal range	No bleeding	Surgery	13	Inappropriate
2	N/A	N/A	N/A	N/A	Bleeding	Surgery	M1	Indeterminate
3	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	No bleeding	Surgery*- Pre-operative lung surgery	13	Inappropriate
4	2.10-5.00	0.50-1.00	N/A	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
5	1.60-2.00	1.10-1.50	Within normal range	Within normal range	No bleeding	Surgery*- Pre-operative for extensive surgery for necrotizing fascitis/sepsis	A2	Appropriate
6	0.50-1.00	N/A	N/A	N/A	No bleeding	Apheresis*- Patient has TTP and to be transferred downtown to UHN for possible Plasmapheresis	A5	Appropriate
			1-2x upper limit of	Within normal		Surgery*- Pre-operative for laparotomy with hemoglobin of		
7	1.10-1.50	1.10-1.50	normal range	range	Bleedina	51	13	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	>10.00	1.60-2.00	N/A	N/A	Minor bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
2	2.10-5.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Miscellaneous*- Bowel perforation	A3	Appropriate
3	5.10-10.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Minor bleeding	Other Bleed*- Bleeding into right knee	A3	Appropriate
4	1.10-1.50	1.10-1.50	Within normal range	Within normal range	Minor bleeding	Coagulopathy (liver disease, DIC, etc)	13	Inappropriate
5	1.60-2.00	1.60-2.00	1-2x upper limit of normal range	Within normal range	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
6	5.10-10.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Minor bleeding	Other Bleed*- Bleeding into right knee	A3	Appropriate
7	2.10-5.00	1.10-1.50	Within normal range	Within normal range	Minor bleeding	Miscellaneous*- Asthma Exacerbation	A3	Appropriate
8	2.10-5.00	1.10-1.50	1-2x upper limit of normal range	N/A	Minor bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
9	2.10-5.00	N/A	1-2x upper limit of normal range	N/A	Minor bleeding	GI Bleed	A3	Appropriate

Site 48

Dite 10											
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result			
			1-2x upper limit of								
1	1.60-2.00	1.60-2.00	normal range	N/A	Unknown	Miscellaneous*- Prematurity	M5	Indeterminate			

Site 49

		-						
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal	Within normal				
1	0.50-1.00	1.10-1.50	range	range	Bleeding	Massive transfusion	M4	Indeterminate
			1-2x upper limit of	1-2x upper limit of	Minor			
2	1.10-1.50	1.10-1.50	normal range	normal range	bleeding	Surgery	13	Inappropriate
			Within normal		Minor	Other Bleed*- Subdural		
3	1.10-1.50	N/A	range	N/A	bleeding	Hematoma	13	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal	Within normal		Anticoagulant Reversal-		
1	2.10-5.00	1.60-2.00	range	range	Bleeding	Warfarin	A1	Appropriate
			>2x upper limit of	1-2x upper limit of		Anticoagulant Reversal-		
2	5.10-10.00	2.10-5.00	normal range	normal range	Unknown	Coumadin	M5	Indeterminate
			1-2x upper limit of	Within normal	No	Surgery*- Pre-op Transurethral		
3	1.10-1.50	1.10-1.50	normal range	range	bleeding	resection of prostate	13	Inappropriate
			Within normal	Within normal	Minor	Anticoagulant Reversal-		
4	2.10-5.00	1.10-1.50	range	range	bleeding	Coumadin	A1	Appropriate

Site 51	1	T	1	1	1			1
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal	Within normal	Minor			
1	1.60-2.00	1.10-1.50	range	range	bleeding	Other Bleed*- Epistaxis	A3	Appropriate
			1-2x upper limit of	Within normal				
2	1.10-1.50	1.10-1.50	normal range	range	Unknown	Surgery	13	Inappropriate
			Within normal	Within normal		Coagulopathy (liver disease,		
3	2.10-5.00	1.60-2.00	range	range	Unknown	DIC, etc)	M5	Indeterminate
			1-2x upper limit of	1-2x upper limit of		Miscellaneous*- Coma/ Altered		
4	1.10-1.50	1.10-1.50	normal range	normal range	Unknown	LOC	13	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of	Within normal				
1	1.60-2.00	1.10-1.50	normal range	range	Bleeding	Surgery	A6	Appropriate
					No	Plasma exchange (therapeutic		
2	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
					No	Plasma exchange (therapeutic		
3	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
			1-2x upper limit of	Within normal				
4	1.60-2.00	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
_			1-2x upper limit of	Within normal				
5	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Surgery	13	Inappropriate
~		4 4 9 4 5 9	1-2x upper limit of	Within normal				
6	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
_		4 00 0 00	1-2x upper limit of	Within normal		Coagulopathy (liver disease,		
7	2.10-5.00	1.60-2.00	normal range	range	Bleeding	DIC, etc)	A3	Appropriate
			1-2x upper limit of	Within normal	No	Coagulopathy (liver disease,		
8	5.10-10.00	1.60-2.00	normal range	range	bleeding	DIC, etc)	M3	Indeterminat
		4 4 9 4 5 9	1-2x upper limit of	Within normal				
9	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
4.0		4 4 9 4 5 9	1-2x upper limit of	Within normal				
10	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
			1-2x upper limit of	Within normal	_			
11	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
			1-2x upper limit of	Within normal	_			
12	1.60-2.00	1.10-1.50	normal range	range	Bleeding	Surgery	A6	Appropriate
			1-2x upper limit of	Within normal	Minor			
13	1.10-1.50	1.10-1.50	normal range	range	bleeding	Surgery	13	Inappropriat
			>2x upper limit of	Within normal	_			
14	5.10-10.00	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
			>2x upper limit of	Within normal	_			
15	5.10-10.00	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
			>2x upper limit of	Within normal	_			
16	5.10-10.00	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
			1-2x upper limit of	1-2x upper limit of				
17	1.10-1.50	1.10-1.50	normal range	normal range	Bleeding	Surgery	13	Inappropriat
			1-2x upper limit of	Within normal	Minor			
18	1.10-1.50	1.10-1.50	normal range	range	bleeding	Surgery	13	Inappropriate
			1-2x upper limit of	Within normal	Minor			
19	1.10-1.50	1.10-1.50	normal range	range	bleeding	Surgery	13	Inappropriat
	N 1/A				No	Plasma exchange (therapeutic		
20	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
					No	Plasma exchange (therapeutic		
21	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
			1-2x upper limit of	Within normal	_			
22	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Surgery	13	Inappropriat
					No	Plasma exchange (therapeutic		
23	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
<u>.</u>			Within normal	Within normal	_			
24	1.10-1.50	1.10-1.50	range	range	Bleeding	Massive transfusion	M4	Indeterminat
a -			1-2x upper limit of	Within normal				
25	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Massive transfusion	A4	Appropriate
			Within normal	Within normal			1.	
26	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriat
					No	Plasma exchange (therapeutic		
27	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
			Within normal	Within normal				
28	1.10-1.50	1.10-1.50	range	range	Bleeding	Surgery	13	Inappropriat

29	N/A	N/A	N/A	N/A	No bleeding	Plasma exchange (therapeutic apheresis)	A5	Appropriate
			1-2x upper limit of	Within normal			10	
30	1.10-1.50	1.10-1.50	normal range	range	Bleeding	Surgery	13	Inappropriate

5110 55								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
						Other Bleed*- Acute intra-		
			Within normal			abdominal hemorrhage with		
1	1.10-1.50	N/A	range	N/A	Bleeding	myeloproliferative disorder	13	Inappropriate
						Other Bleed*- Massive intra-		
			Within normal			abdominal hemorrhage with		
2	1.10-1.50	N/A	range	N/A	Bleeding	myeloproliferative disorder	13	Inappropriate

Site 54

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Surgery	A6	Appropriate
	1.00-2.00	1.10-1.50	1-2x upper limit of	nonnarrange	No	Anticoagulant Reversal-	70	Appropriate
2	>10.00	N/A	normal range	N/A	bleeding	Warfarin	11	Inappropriate
3	N/A	1.60-2.00	N/A	1-2x upper limit of normal range	Bleeding	Surgery	A6	Appropriate
4	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
5	2.10-5.00	N/A	N/A	N/A	No bleeding	Liver biopsy	A2	Appropriate
6	1.10-1.50	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery*- Left radical nephrectomy; repair renal vein	13	Inappropriate
7	1.10-1.50	N/A	>2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Heparin	14	Inappropriate
8	1.60-2.00	1.10-1.50	N/A	Within normal range	Bleeding	Surgery	A6	Appropriate
9	1.10-1.50	N/A	N/A	N/A	Bleeding	Surgery	13	Inappropriate

Site 55								
#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			Within normal					
1	1.10-1.50	N/A	range	N/A	Bleeding	Surgery	13	Inappropriate

Site 56

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
			1-2x upper limit of	1-2x upper limit of	No	Anticoagulant Reversal-		
1	2.10-5.00	1.60-2.00	normal range	normal range	bleeding	Warfarin	11	Inappropriate
			1-2x upper limit of	1-2x upper limit of	No	Coagulopathy (liver disease,		
2	2.10-5.00	1.60-2.00	normal range	normal range	bleeding	DIC, etc)	M3	Indeterminate
			1-2x upper limit of	Within normal	No			
3	1.60-2.00	1.10-1.50	normal range	range	bleeding	Surgery	A2	Appropriate
			1-2x upper limit of		No	Anticoagulant Reversal-		
4	2.10-5.00	1.10-1.50	normal range	N/A	bleeding	Warfarin	l1	Inappropriate
			Within normal		Minor			
5	2.10-5.00	1.60-2.00	range	N/A	bleeding	Surgery	A6	Appropriate
			1-2x upper limit of	1-2x upper limit of	No			
6	1.10-1.50	1.10-1.50	normal range	normal range	bleeding	Surgery	13	Inappropriate
			1-2x upper limit of		No	Anticoagulant Reversal-		
7	2.10-5.00	1.10-1.50	normal range	N/A	bleeding	Coumadin	11	Inappropriate
			1-2x upper limit of		No	Coagulopathy (liver disease,		
8	2.10-5.00	N/A	normal range	N/A	bleeding	DIC, etc)	M3	Indeterminate

0	site 57								
	#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
				>2x upper limit of			Coagulopathy (liver disease,		
	1	1.60-2.00	N/A	normal range	N/A	Bleeding	DIC, etc)	A3	Appropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
2	2.10-5.00	N/A	1-2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
3	1.10-1.50	N/A	Within normal range	N/A	Bleeding	Coagulopathy (liver disease, DIC, etc)	13	Inappropriate
4	2.10-5.00	1.10-1.50	>2x upper limit of normal range	1-2x upper limit of normal range	No bleeding	Anticoagulant Reversal- Coumadin	11	Inappropriate
6	1.60-2.00	N/A	1-2x upper limit of normal range	N/A	Bleeding	Coagulopathy (liver disease, DIC, etc)	A3	Appropriate
10	2.10-5.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
12	1.10-1.50	N/A	N/A	N/A	No bleeding	Miscellaneous*- Obstructive jaundice, Atrial fibrillation history	13	Inappropriate
13	>10.00	N/A	1-2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate

Site 59 Pre-INR Post-INR Post-aPTT # Pre-aPTT Indication Code Result Procedure Indication >2x upper limit of No Anticoagulant Reversal->10.00 N/A N/A bleeding 11 Inappropriate 1 normal range Unknown 1-2x upper limit of 1-2x upper limit of 1.60-2.00 2.10-5.00 normal range normal range Bleeding A6 Appropriate 2 Surgery >2x upper limit of 3 N/A N/A normal range Bleeding M1 Indeterminate N/A Surgery 1-2x upper limit of normal range 1.60-2.00 1.60-2.00 N/A Bleeding A6 4 Surgery Appropriate 1-2x upper limit of Within normal Surgery*- Post cardiac surgery Bleeding 1.60-2.00 1.10-1.50 normal range bleeding A3 5 range Appropriate Within normal Minor bleeding 13 6 1.10-1.50 1.10-1.50 Pleural effusion N/A range Inappropriate >2x upper limit of 1-2x upper limit of 7 >10.00 1.60-2.00 normal range normal range Bleeding Surgery A6 Appropriate 1-2x upper limit of Minor Within normal 1.60-2.00 8 1.10-1.50 normal range range bleeding Surgery A6 Appropriate 1-2x upper limit of 9 N/A 1.60-2.00 N/A normal range Bleeding Surgery A6 Appropriate 1-2x upper limit of Within normal 10 1.60-2.00 1.10-1.50 normal range range Bleedina Surgery A6 Appropriate 1-2x upper limit of 1-2x upper limit of normal range 11 1.60-2.00 1.60-2.00 normal range Bleeding Surgery A6 Appropriate 1-2x upper limit of Minor Other Bleed*- Post arrest; 1.60-2.00 bleeding A3 12 N/A normal range N/A bleed? Appropriate Surgery*- Abdominal aortic 1-2x upper limit of Minor 1.10-1.50 N/A N/A bleeding 13 Inappropriate 13 normal range aneurysm 1-2x upper limit of 14 N/A 1.10-1.50 N/A normal range Bleeding Surgery M2 Indeterminate Within normal 15 2.10-5.00 1.10-1.50 N/A Bleeding GI Bleed A3 Appropriate range 1-2x upper limit of 1-2x upper limit of Minor 1.10-1.50 1.10-1.50 normal range bleeding Surgery*- Post cardiac surgery 13 Inappropriate 16 normal range Within normal Within normal 13 17 1.10-1.50 1.10-1.50 Bleeding GI Bleed Inappropriate range range Within normal Within normal Minor 1.10-1.50 1.10-1.50 bleeding GI Bleed 13 18 Inappropriate range range Minor 13 19 1.10-1.50 N/A N/A N/A bleeding GI Bleed Inappropriate 1-2x upper limit of 13 1.10-1.50 1.10-1.50 N/A 20 normal range Unknown Unknown Inappropriate Within normal Within normal Minor 21 1.60-2.00 1.10-1.50 bleeding Surgery*- Post cardiac surgery A3 Appropriate range range 1-2x upper limit of Within normal Other Bleed*- hemorrhage 1.10-1.50 1.10-1.50 Bleeding 13 22 normal range range during delivery Inappropriate Within normal No 23 1.60-2.00 1.60-2.00 N/A bleeding Sepsis M3 Indeterminate range 1-2x upper limit of Minor Other Bleed*- Subdural Appropriate 24 2.10-5.00 1.10-1.50 normal range N/A bleeding Hematoma A3

				Within normal	Minor			
25	N/A	1.10-1.50	N/A	range	bleeding	Surgery*- Post cardiac surgery	M2	Indeterminate
						Miscellaneous*- Intestinal		
26	N/A	N/A	N/A	N/A	Unknown	metaplasia	M1	Indeterminate
			Within normal	Within normal	Minor			
27	1.10-1.50	1.10-1.50	range	range	bleeding	GI Bleed	13	Inappropriate
			Within normal		Minor			
28	0.50-1.00	N/A	range	N/A	bleeding	GI Bleed	12	Inappropriate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
					No			
1	N/A	N/A	N/A	N/A	bleeding	Leukemia*- ALL	M1	Indeterminate
					No			
2	N/A	N/A	N/A	N/A	bleeding	Leukemia*- ALL	M1	Indeterminate
					No			
3	N/A	N/A	N/A	N/A	bleeding	Leukemia*- ALL	M1	Indeterminate
					No			
4	N/A	N/A	N/A	N/A	bleeding	Leukemia*- ALL	M1	Indeterminate
					No			
5	N/A	N/A	N/A	N/A	bleeding	Unknown	M1	Indeterminate

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	N/A	N/A	N/A	N/A	Unknown	Thoracentesis	M1	Indeterminate
2	N/A	1.60-2.00	N/A	1-2x upper limit of normal range	Bleeding	Surgery	A6	Appropriate
3	1.10-1.50	N/A	Within normal range	N/A	Unknown	Leukemia*- Refractory AML	13	Inappropriate
4	2.10-5.00	2.10-5.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Liver Transplant	A3	Appropriate
5	2.10-5.00	1.60-2.00	1-2x upper limit of normal range	N/A	Unknown	Surgery*- Possible cardiac by- pass	A2	Appropriate
6	2.10-5.00	1.10-1.50	Within normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
7	2.10-5.00	N/A	1-2x upper limit of normal range	N/A	Bleeding	Liver Transplant	A3	Appropriate
8	0.50-1.00	N/A	Within normal range	N/A	No bleeding	Plasma exchange (therapeutic apheresis)	A5	Appropriate
9	1.60-2.00	1.10-1.50	Within normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
10	N/A	1.10-1.50	N/A	1-2x upper limit of normal range	Bleeding	Liver Transplant	M2	Indeterminate
11	N/A	N/A	N/A	N/A	Bleeding	Liver Transplant	M1	Indeterminate
12	2.10-5.00	1.10-1.50	Within normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
13	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	1-2x upper limit of normal range	Unknown	Unknown	M5	Indeterminate
14	N/A	1.60-2.00	N/A	Within normal range	Bleeding	Surgery	A6	Appropriate
15	0.50-1.00	N/A	Within normal range	N/A	No bleeding	Plasma exchange (therapeutic apheresis)	A5	Appropriate
16	1.60-2.00	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Unknown	A3	Appropriate
17	1.60-2.00	1.60-2.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Surgery	A6	Appropriate
18	N/A	1.60-2.00	N/A	1-2x upper limit of normal range	Bleeding	Liver Transplant	A3	Appropriate
19	1.60-2.00	2.10-5.00	1-2x upper limit of normal range	1-2x upper limit of normal range	Bleeding	Liver Transplant	A3	Appropriate
20	1.60-2.00	1.10-1.50	1-2x upper limit of normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
21	N/A	N/A	N/A	N/A	Unknown	Unknown	M1	Indeterminate
22	0.50-1.00	1.60-2.00	Within normal range	Within normal range	Bleeding	Surgery	A6	Appropriate
23	N/A	N/A	N/A	N/A	No bleeding	Plasma exchange (therapeutic apheresis)	A5	Appropriate

24	N/A	N/A	N/A	N/A	No bleeding	Plasma exchange (therapeutic apheresis)	A5	Appropriate
				Within normal		Miscellaneous*- End stage		
25	N/A	1.10-1.50	N/A	range	Bleeding	renal disease	M2	Indeterminate
			Within normal	Within normal	_			
26	1.60-2.00	1.10-1.50	range	range	Bleeding	Liver Transplant	A3	Appropriate
27	1 60 2 00	1 60 2 00	>2x upper limit of	1-2x upper limit of	Dlaading	Surgery	46	Appropriate
27	1.60-2.00	1.60-2.00	normal range Within normal	normal range 1-2x upper limit of	Bleeding	Surgery	A6	Appropriate
28	1.60-2.00	0.50-1.00	range	normal range	Bleeding	Surgery	A6	Appropriate
			Within normal	1-2x upper limit of	Dieballig		7.0	, ippropriate
29	2.10-5.00	1.60-2.00	range	normal range	Bleeding	GI Bleed	A3	Appropriate
				1-2x upper limit of		Other Transplant*- Double lung		
30	N/A	1.60-2.00	N/A	normal range	Bleeding	transplant	A3	Appropriate
			1-2x upper limit of	1-2x upper limit of	No			
31	2.10-5.00	1.60-2.00	normal range	normal range	bleeding	Thoracentesis	A2	Appropriate
20	4 60 0 00	4 40 4 50	1-2x upper limit of	1-2x upper limit of	Dissilian	Surgery*- Post cardiovascular	4.0	Annensiste
32	1.60-2.00	1.10-1.50	normal range 1-2x upper limit of	normal range	Bleeding No	surgery Miscellaneous*-	A3	Appropriate
33	2.10-5.00	N/A	normal range	N/A	bleeding	Oesophagogastoduodenoscopy	A2	Appropriate
00	2.10 0.00	1.177	normanange		No	Plasma exchange (therapeutic	7.2	rippropriate
34	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
			Within normal	1-2x upper limit of		Surgery*- Abdominal aortic		
35	0.50-1.00	1.10-1.50	range	normal range	Bleeding	aneurysm	12	Inappropriate
36	N/A	N/A	N/A	N/A	Bleeding	Liver Transplant	M1	Indeterminate
					No	Plasma exchange (therapeutic		
37	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
				Within normal				
38	2.10-5.00	1.10-1.50	N/A	range	Bleeding	Surgery	A6	Appropriate
20	2 10 5 00	1 60 2 00	>2x upper limit of	Within normal	Dlaading	Surgery	A6	Appropriate
39	2.10-5.00	1.60-2.00	normal range	range	Bleeding No	Surgery Plasma exchange (therapeutic	AO	Appropriate
40	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
40	19/7				No	Plasma exchange (therapeutic	710	Appropriate
41	N/A	N/A	N/A	N/A	bleeding	apheresis)	A5	Appropriate
			1-2x upper limit of	1-2x upper limit of		Other Transplant*- Double lung		
42	1.60-2.00	1.10-1.50	normal range	normal range	Bleeding	transplant	A3	Appropriate
				1-2x upper limit of				
43	N/A	1.10-1.50	N/A	normal range	Bleeding	Surgery	M2	Indeterminate
	0 40 5 00	4 00 0 00	Within normal	N1/A	No		140	1
44	2.10-5.00	1.60-2.00	range	N/A	bleeding	Unknown	M3	Indeterminate
Site 62								
#	Pre-INR	Deat IND	Pre-aPTT	Post-aPTT	Indiantian	Procedure Indication	Codo	Deput
#	Ple-link	Post-INR	1-2x upper limit of	Within normal	Indication	Procedure indication	Code	Result
1	1.60-2.00	1.10-1.50	normal range	range	Bleeding	Surgery	A6	Appropriate
2	1.10-1.50	N/A	N/A	N/A	Unknown	Surgery	13	Inappropriate
2	1.10-1.00	11/71	1-2x upper limit of	1-2x upper limit of	UTKIOWI		10	парріорнате
3	1.60-2.00	0.50-1.00	normal range	normal range	Bleeding	Surgery	A6	Appropriate
•			1-2x upper limit of	1-2x upper limit of		3,		
4	1.60-2.00	1.60-2.00	normal range	normal range	Bleeding	Surgery	A6	Appropriate
		T	1-2x upper limit of	1-2x upper limit of	J			
5	1.60-2.00	1.10-1.50	normal range	normal range	Bleeding	Surgery	A6	Appropriate
			1-2x upper limit of	1-2x upper limit of				
6	1.60-2.00	N/A	normal range	normal range	Bleeding	Surgery	A6	Appropriate
-	N1/A	4 40 4 50		Within normal	Discriber	Current .	MO	la data mula t
7	N/A	1.10-1.50	N/A N/A		Bleeding	Surgery Disural offusion	M2 M5	Indeterminate
0		1 NI/A	I NI/A	I NI/A		L Blourol offusion	1 1 1 5	I Indeterminete

9

8 5.10-10.00

1.10-1.50

N/A

1.10-1.50

N/A

range

Within normal

	#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
ſ				Within normal					
	1	0.50-1.00	N/A	range	N/A	Bleeding	GI Bleed	12	Inappropriate

Unknown

Bleeding

Pleural effusion

Surgery

M5

13

Indeterminate

Inappropriate

N/A Within normal

range

#	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
1	5.10-10.00	N/A	N/A	N/A	No bleeding	Anticoagulant Reversal- Unknown	11	Inappropriate
2	5.10-10.00	N/A	>2x upper limit of normal range	N/A	Unknown	Anticoagulant Reversal- Coumadin	M5	Indeterminate
3	2.10-5.00	N/A	>2x upper limit of normal range	N/A	Bleeding	Anticoagulant Reversal- Coumadin	A1	Appropriate
ite 65 #	Pre-INR	Post-INR	Pre-aPTT	Post-aPTT	Indication	Procedure Indication	Code	Result
	Pre-INR 2.10-5.00	Post-INR N/A	Pre-aPTT N/A	Post-aPTT N/A	Indication Unknown	Procedure Indication	Code M5	Result Indeterminate
ite 65 # 1 2						Procedure Indication		Indeterminate
# 1	2.10-5.00	N/A	N/A N/A N/A	N/A	Unknown	Procedure Indication Surgery	M5	Indeterminate Indeterminate
# 1 2	2.10-5.00 N/A	N/A N/A	N/A N/A	N/A N/A	Unknown Unknown Minor		M5 M1	Result Indeterminate Indeterminate Indeterminate Inappropriate

Unknown

Unknown

Unknown

Surgery

M1

M5

13

Indeterminate

Indeterminate

Inappropriate

N/A

N/A

N/A

* Denotes Procedure/Indication Re-classified

N/A

N/A

1.10-1.50

5 N/A

6

7

1.60-2.00

1.10-1.50

Site 66-76- Reported no plasma orders during the audit period.

range

N/A

N/A

References:

- 1. McClelland, DBL. Effective use of blood components. In: Practical Transfusion Medicine, 1st Ed. Ed. Murphy M and Pamphilon D. Blackwell, Oxford, 2001, 65-76.
- 2. Canadian Blood Services. Circular of Information for the use of human blood and blood components. <u>www.blood.ca</u> 2005; 41-45.
- 3. Eder AF, Sebok MA. Plasma components: FFP, FP24, and thawed plasma. Immunohematology 2007; 23: 150-157.
- 4. Holland L, Warkentin TE, Refaai M et al. Sub-optimal effect of a three-factor prothrombin complex concentrate (Profilnine SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49: 1171-1177.
- 5. Canadian Blood Services. Important information regarding the availability of Octaplex. Customer letter #2008-22, 2008-07-31 www.blood.ca
- 6. National Advisory Committee on Blood and Blood Products. Recommendations for use of Octaplex in Canada. September 16, 2008. <u>www.transfusionontario.org</u>
- Stanworth SJ. The evidence based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology. The American Society of Hematology Education Program Book. 2007; 179-186.
- 8. Luk C, Eckert KM, Barr RM, Chin-Yee IH. Prospective audit of the use of fresh frozen plasma based on Canadian Medical Association Guidelines. CMAJ 2002; 166: 1539-1540.
- 9. Lauzier F, Cook D, Griffith L et al. Fresh frozen plasma transfusion in critically ill patients. Crit Care Med 2007; 35:1655-1659.
- 10. Palo R, Capraro L, Hovileto S et al. Population-based audit of fresh-frozen plasma transfusion practices. Transfusion 2006; 46: 1921-1925.
- 11. Canadian Blood Services. Personal Communication.
- 12. Canadian Blood Services. Disposition data for fiscal year 2007
- 13. Canadian Blood Services. Disposition data for fiscal year 2008
- 14. Stanworth SJ, Brunskill SJ, Hyde CJ et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Brit J Haematol 2004; 126: 139-152.
- 15. Abdel-Waheb OI, Healy B, Dzik WH. Effect of fresh frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46: 1279-1285.
- 16. Cheng CK, Sadek I. Fresh-frozen plasma transfusion in patients with mild coagulation abnormalities at a large Canadian transfusion center. Transfusion 2007; 47: 748.
- 17. De Backer D, Vanderkerckhove B, Stanworth S et al. Guidelines for the use of fresh frozen plasma. Acta Clin Belg 2008; 63: 381-390.
- 18. Youssef WI, Salazar F, Dasarethy S et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterology 2003; 98: 1391-1394.
- 19. Chowdhury P, Saayman AG, Paulus U et al. Efficacy of a standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of hemostasis in critically ill patients. Brit J Haematol 2004; 125: 69-73.
- 20. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion. The effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006; 126: 133-139
- 21. Schulman S, Bijsetrveld NR. Anticoagulants and their reversal. Transf Med Rev 2007; 21: 37-48.
- 22. Callum JL, Pinkerton PH. Bloody Easy 2. Blood transfusions, blood alternatives and transfusion reactions. A guide to transfusion medicine. 2nd Ed. 2005; Sunnybrook and Women's College Health Sciences Center.

- 23. Kleinman S, Caulfield T, Chan P et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44: 1774-1789.
- 24. Serious Hazards of Transfusion (SHOT) Annual Report. 2006. www.shot-uk.org
- 25. Popovsky MA. Pulmonary consequences of transfusion: TRALI and TACO. Transf Aph Sci 2006; 34: 243-244.
- 26. Audet AM, Andrzejewski C, Popovsky MA. Red blood cell transfusion practices in patients undergoing orthopedic surgery; a multi-institutional analysis. Orthopedics 1998; 21: 851-858.
- Auroy Y, Lienhart A, Pequignot F. Benhamou D. Complications related to blood transfusionin surgical patients: data from the French national survey on anesthesia related deaths. Transfusion 2007; 47 (Suppl. 2); 184S-189S.
- Robillard P, Nawej KI, Chapdelaine A. Transfusion-associated circulatory overload (TACO); current leading cause of transfusion-associated fatalities reported to the Quebec Hemovigilance System. Proc. 30th Ann Conf of the Canadian Soc Transf Med. Ottawa June 4-7, 2009. Oral Presentation Abst. 10, p51.
- 29. British Committee for Standards in Haematology. Guidelines for the use of fresh frozen plasma. Transf Med 1992; 2: 57-63.
- 30. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Brit J Haematol 2004; 126: 11-28.
- 31. College of American Pathologists. Fresh frozen plasma, cryoprecipitate, and platelet administrative practice guidelines development task force. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. JAMA 1994; 271: 777-781.
- 32. Canadian Medical Association. Expert working group. Guidelines for red blood cell and plasma transfusion for adults and children. CMAJ 1997; 156 (Suppl. 11): S1-S4.
- 33. Australian National Health and Medical Research Council and Australian Society of Blood Transfusion Clinical Practice Guidelines. Appropriate use of fresh frozen plasma and cryoprecipitate. 2001. www.nhmrc.gov.au/publications
- 34. American Society of Anesthesiologists. Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on blood component therapy. Anesthesiology 1996; 85: 441-442.
- 35. Jones HP, Jones J, Napier JA, al-Ismail S. Clinical use of FFP: results of a retrospective process and outcome audit. Transf Med 1998; 8: 37-41.
- 36. Prabitha R, Jayaranee S Ramesh JC et al. An audit of fresh frozen plasma usage in a tertiary referral centre in a developing country. Malays J Pathol 2001; 23: 41-46.
- 37. Schofield WN, Rubin GL, Dean MG. Appropriateness of platelet, fresh frozen plasma and cryoprecipitate transfusion in New South Wales public hospitals. Med J Aust 2003; 178: 117-121.
- 38. Chng WJ, Tan MK, Kuperan P. An audit of fresh frozen plasma usage in an acute general hospital in Singapore. Singapore Med J 2003; 44: 574-578.
- 39. Kakkar N, Kaur R, Dhanoa J. Improvement in fresh frozen plasma transfusion practice: results of an outcome audit. Transf Med 2004; 14: 231-235.
- 40. Hui CH, Williams I, Davis K. Clinical audit of the use of fresh frozen plasma and platelets in a tertiary teaching hospital and the impact of a new transfusion request form. Intern Med J 2005; 35: 283-288.
- 41. Atkinson S. An audit of fresh frozen plasma transfusion use at the Royal Hospital Trust (RGHT). Transf Med 2006; 16 (S1):30, abst P12.

42. Yeh CJ, Wu CF, Hsu LL et al. Transfusion audit of fresh-frozen plasma in Southern Taiwan. Vox Sang 2006; 91: 270-274.